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SEM image of deep etched 190umx190um openings.
FIG. 11
Optical image of front surface of nDS device after anodic bonding.
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Optical image of inlet channel openings
under bonded and lapped glass film.
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NANOCHANNELED DEVICE AND RELATED
METHODS
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a Continuation of U.S. patent appli-
cation Ser. No. 12/618,233, filed Nov. 13, 2009, now U.S.
Pat. No. 8,480,637, entitled "Nanochanneled Device and
Related Methods", U.S. Provisional Patent Application Ser.
No. 61/114,687, filed Nov. 14, 2008, entitled "Nanochan-
neled Device and Method of Use", and U.S. Provisional
Patent Application Ser. No. 61/168,844, filed Apr. 13, 2009,
entitled "Nanochanneled Device and Method of Use", the
entire disclosures of which are specifically incorporated
herein by reference.
This invention was made with government support under
contract NNJ06HE06A awarded by NASA. The government
has certain rights in this invention.
BACKGROUND INFORMATION
Considerable advances have been made in the field of
therapeutic agent (e.g. drug) delivery technology over the
last three decades, resulting in many breakthroughs in clini-
cal medicine. The creation of therapeutic agent delivery
devices that are capable of delivering therapeutic agents in
controlled ways is still a challenge. One of the major
requirements for an implantable drug delivery device is
controlled release of therapeutic agents, ranging from small
drug molecules to larger biological molecules. It is particu-
larly desirable to achieve a continuous passive drug release
profile consistent with zero order kinetics whereby the
concentration of drug in the bloodstream remains constant
throughout an extended delivery period.
These devices have the potential to improve therapeutic
efficacy, diminish potentially life-threatening side effects,
improve patient compliance, minimize the intervention of
healthcare personnel, reduce the duration of hospital stays,
and decrease the diversion of regulated drugs to abusive
uses.
Nanochannel delivery devices may be used in drug deliv-
ery products for the effective administration of drugs. In
addition, nanochannel delivery devices can be used in other
applications where controlled release of a substance over
time is needed.
SUMMARY
Embodiments of this invention comprise a nanochannel
delivery device having nanochannels within a structure
configured to yield high mechanical strength and high flow
rates. Various fabrication protocols may be used to form the
nanochannel delivery device. Embodiments of the fabricated
devices feature horizontal nanochannel lay-out (e.g., the
nanochannel is parallel to the primary plane of the device),
high molecule transport rate, high mechanical strength,
optional multilayered lay-out, amenability to select channel
lining materials, and possible transparent top cover. Based
on silicon microfabrication technology, the dimensions of
the nanochannel area as well as concomitant microchannel
areas can be precisely controlled, thus providing a predict-
able, reliable, constant release rate of drug (or other) mol-
ecules over an extended time period. In certain embodi-
ments, the nanochannel delivery device can be used to build
a multilayered nanochannel structure. Multilayered nano-
channel structures can extend the limit of release rate range
N
of a single layer nanochannel delivery device or system, and
allow a wide range of pre-defined porosity to achieve an
arbitrary release rate using any preferred nanochannel size.
In certain embodiments, the nanochannel delivery device
5 is made of a "sandwich" of materials, composed of a thin top
layer, the horizontal nanochannels, and a thicker bottom
wafer. The thin top layer can house an array of microchan-
nels that offer an inlet or outlet for diffusing molecules. It
can also serve as the lid or ceiling for the nanochannels by
io providing the channels' top surface. The thicker bottom
wafer can house an array of microchannels that offer a
collateral outlet or inlet. Note that in the following, inlets are
indicated in the bottom wafer and outlets are indicated in the
top layer, but this is not a limit of the invention. In certain
15 embodiments, the nanochannels are fabricated by a sacrifi-
cial layer technique that provides smooth surfaces and
precisely controlled dimensions. The nanochannels can be
formed in between the two layers and connect the outlet
microchannels with the array of inlet microchannels formed
20 in the bottom wafer, additionally allowing thin surface
layers to be applied to both the top and the bottom surfaces
independently, in order to optimize channel properties such
as surface charge, hydrophobicity, wetting and conductivity.
Each inlet and outlet microchannel can be connected to one,
25 two, or more nanochannels. The height, width, and length of
the nanochannel can be used to maintain a constant (zero-
order) delivery. By the help of nanofabrication, a nanochan-
nel length of 10 nm or less is feasible.
In certain embodiments, the nanochannel delivery device
30 is designed to yield high strength. This can be achieved by
a supporting structure obtained in the bottom side of the
thick wafer. The structure can be composed by a regular
mesh of micrometric walls which create the side surfaces of
larger inlet macrochannels. Moreover, the top portion of the
35 bottom wafer (in or on which nanochannels may be fabri-
cated) can be engineered to provide good mechanical sta-
bility.
The thickness of the supporting layer underneath the
nanochannels can be optimized, and can be realized by
40 controlling the depth of the inlet microchannels and outlet
macrochannels or by selecting an SOI wafer with appropri-
ate depth of buried oxide layer. The materials and thickness
of top layers is also optimized for the attributes noted above.
Certain embodiments include a nanochannel delivery
45 device comprising: an inlet microchannel; a nanochannel;
and an outlet microchannel, wherein the inlet microchannel
and the outlet microchannel are in direct fluid communica-
tion with the nanochannel. In specific embodiments, the
nanochannel is oriented parallel to the primary plane of the
5o nanochannel delivery device. In particular embodiments, a
flow path from the inlet microchannel to the nanochannel to
the outlet microchannel requires a maximum of two changes
in direction.
In specific embodiments, the inlet microchannel has a
55 length, a width, and a depth; the outlet microchannel has a
length, a width, and a depth; and the nanochannel has a
length, a width, and a depth. In certain embodiments, the
ratio of the nanochannel length to the inlet microchannel
length is between 0.01 and 10.0, and the ratio of the
6o nanochannel length to the outlet microchannel length is
between 0.01 and 10.0. In particular embodiments, the
nanochannel length is greater than the inlet microchannel
length and the nanochannel length is greater than the outlet
microchannel length. In specific embodiments, the ratio of
65 the nanochannel length to either the inlet microchannel
length or the outlet microchannel length is between 0.2 and
5.0, between 0.3 and 3.0, between 0.4 and 2.0, or between
US 9,526,824 B2
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0.5 and 1.0. In certain embodiments, the nanochannel length
is greater than the length, width, and depth of the outlet
microchannel. In particular embodiments, the inlet micro-
channel is in direct fluid communication with the outlet
microchannel via a single nanochannel.
Certain embodiments include a nanochannel delivery
device comprising: an inlet microchannel; a nanochannel; an
outlet microchannel; and a fluid flow path from the inlet
microchannel to the outlet microchannel, where the fluid
flow path requires a maximum of two changes in direction.
In specific embodiments, the nanochannel is oriented par-
allel to the primary plane of the nanochannel delivery
device. In particular embodiments, the inlet microchannel
and the outlet microchannel are in direct fluid communica-
tion with the nanochannel.
Certain embodiments include a nanochannel delivery
comprising: a substantially planar body comprising a first
surface and a second surface opposing the first surface; a
nanochannel disposed within the substantially planar body;
an inlet microchannel in fluid communication with the
nanochannel; and an outlet microchannel in fluid commu-
nication with the nanochannel. In particular embodiments,
the inlet microchannel extends from the nanochannel to the
first surface and wherein the outlet microchannel extends
from the nanochannel to second surface.
Certain embodiments include a nanochannel delivery
device comprising: a plurality of inlet microchannels; a
plurality of nanochannels; and a plurality of outlet micro-
channels, where each inlet microchannel is in direct fluid
communication with an outlet microchannel via a single
nanochannel. In particular embodiments, the nanochannel is
oriented parallel to the primary plane of the nanochannel
delivery device, and/or an inlet microchannel and an outlet
microchannel are in direct fluid communication with a
common nanochannel. In particular embodiments, indi-
vidual inlet and outlet microchannels are arranged perpen-
dicular to a primary plane of the nanochannel delivery
device; the plurality of inlet microchannels form a first
array; the plurality of outlet microchannels form a second
array; and the first array and the second array are overlap-
ping so that individual inlet microchannels are distributed
between individual outlet microchannels when viewed along
a section taken perpendicular to the primary plane.
Certain embodiments include a nanochannel delivery
device comprising: a substantially planar body including: a
length, a width, and a thickness, wherein the length and the
width are each greater than the thickness; an inlet surface on
a first side of the substantially planar body, wherein the inlet
surface is bounded by the length and the width of the
substantially planar body; and an outlet surface on a second
side of the substantially planar body. In particular embodi-
ments, the outlet surface is bounded by the length and the
width of the substantially planar body, and the inlet surface
is substantially parallel with the outlet surface. Specific
embodiments comprise a nanochannel disposed within the
substantially planar body, where the nanochannel comprises
an inlet end and an outlet end; an inlet microchannel in fluid
communication with the nanochannel; and an outlet micro-
channel in fluid communication with the nanochannel,
where the inlet microchannel and nanochannel are config-
ured such that a first linear axis can extend between the inlet
surface and the inlet end of the nanochannel. In particular
embodiments, the outlet microchannel and nanochannel are
configured such that a second linear axis can extend between
the outlet surface and the outlet end of the nanochannel. In
certain embodiments, a primary axis of the inlet microchan-
nel is perpendicular to a plane that is parallel to the sub-
_►,
stantially planar body. Particular embodiments comprise an
inlet macrochannel between the inlet surface and the inlet
microchannel, where the inlet macrochannel comprises
boundary walls that are generally perpendicular to the inlet
5 surface. In specific embodiments, the inlet macrochannel is
formed by deep reactive-ion etching. In particular embodi-
ments, a primary axis of the outlet microchannel is perpen-
dicular to a plane that is parallel to the substantially planar
body.
10 Certain embodiments comprise an apparatus comprising a
first nanochannel delivery device inserted into a capsule. In
particular embodiments, the first nanochannel delivery
device is installed perpendicular to the primary axis of the
capsule. In particular embodiments, the capsule comprises a
15 septum. In certain embodiments, the septum comprises a
self-sealing material. In specific embodiments, the septum
comprises silicone rubber. In certain embodiments, the sep-
tum is configured to receive an injection of a therapeutic
agent.
20 Particular embodiments comprise a cap covering the
septum. In certain embodiments, the cap comprises an
orifice configured to guide a needle towards the septum. In
specific embodiments, the capsule comprises a cover
extending over the first nanochannel delivery device. In
25 particular embodiments, the cover comprises one or more
orifices. In certain embodiments, the one or more orifices are
sized so that they do not limit diffusion of a therapeutic agent
from the capsule during use. In certain embodiments, the
cover is configured to protect the first nanochannel delivery
so device from mechanical damage. In particular embodiments,
the cover is configured to protect the first nanochannel
delivery device from incursion by biological tissue struc-
tures after the capsule has been implanted in a living body.
In certain embodiments, the capsule comprises a first inner
35 reservoir. In specific embodiments, the first nanochannel
delivery device is in fluid communication with the first inner
reservoir.
In specific embodiments, the capsule comprises a second
inner reservoir in fluid communication with a second nano-
40 channel delivery device. In certain embodiments, the first
and second inner reservoir are not in fluid communication
with each other. In particular embodiments, the first and
second inner reservoir are separated by a wall. In specific
embodiments, the first inner reservoir contains a first thera-
45 peutic agent and the second inner reservoir comprises a
second therapeutic agent. In particular embodiments, the
first nanochannel delivery is configured to diffuse a first
therapeutic agent at a first diffusion rate and the second
nanochannel delivery device is configured to diffuse the
50 second therapeutic agent a second diffusion rate.
In certain embodiments the volume of the first inner
reservoir can be modified by replacing a first removable
component of the capsule with a larger removable compo-
nent. In particular embodiments, the first inner reservoir
55 comprises a coating compatible with a therapeutic sub-
stance. In specific embodiments, the capsule comprises an
outer coating configured to prevent deleterious tissue encap-
sulation. In particular embodiments, the capsule comprises a
cylindrical shape. In certain embodiments, the capsule com-
bo prises a disc shape. In certain embodiments, the capsule
comprises a rectangular surface and an arched surface. In
specific embodiments, the capsule comprises a uniform
cross-section.
In certain embodiments, the capsule comprises one or
65 more of the following materials: stainless steel, titanium,
polyetheretherkeytone, polysulfone, epoxy, silicone rubber,
polyetherketoneketone, and thermoplastic polyurethane. In
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particular embodiments, the capsule comprises an anchor
member. In certain embodiments, the anchor member is
configured to receive a suture. In specific embodiments, the
capsule comprises a color coding to indicate a characteristic
of the capsule or the nanochannel delivery device. In par-
ticular embodiments, the color coding indicates a character-
istic of a therapeutic agent contained within the capsule. In
specific embodiments the capsule comprises a translucent or
transparent cover extending over the first nanochannel deliv-
ery device.
Certain embodiments include a method of fabricating a
nanochannel delivery device. In particular embodiments, the
method comprises: providing a first substrate; forming a
plurality of nanochannels in the first substrate; forming a
plurality of inlet microchannels in the nanochannels of the
first substrate; providing a second substrate; forming a
plurality of outlet microchannels in the second substrate; and
coupling the second substrate to the first substrate, wherein
each inlet microchannel is in direct fluid communication
with a nanochannel.
In particular embodiments of the method, the first sub-
strate comprises a silicon-on-insulator wafer. In certain
embodiments, the height of each nanochannel is between
approximately one and ten nanometers. In specific embodi-
ments, the height of each nanochannel is between approxi-
mately ten and twenty nanometers, between approximately
twenty and thirty nanometers, between approximately thirty
and fifty nanometers, between approximately fifty and one
hundred nanometers, or between approximately one hundred
and two hundred nanometers. In certain embodiments the
second substrate comprises a sacrificial release layer of
indium tin oxide film on silicon. Particular embodiments
further comprise depositing a glass film on the second
substrate prior to forming the plurality of inlet microchan-
nels in the second substrate. In specific embodiments, the
second substrate comprises a glass wafer and the glass wafer
is bonded to the first substrate and the glass wafer is ground
to reduce the thickness prior to forming the plurality of
outlet microchannels.
Certain embodiments include a method of fabricating a
nanochannel delivery device where the method comprises:
providing first substrate; forming a plurality of nanochannels
on the first substrate; filling in the plurality of nanochannels
with a first sacrificial material; forming a plurality of inlet
microchannels in the first substrate; filling in the plurality of
inlet microchannels with a second sacrificial material; form-
ing a capping layer that covers the plurality of nanochannels;
forming a plurality of outlet microchannels in the capping
layer; removing the first sacrificial material from the plu-
rality of nanochannels; and removing the second sacrificial
material from the plurality of inlet microchannels.
In particular embodiments of the method, an inlet micro-
channel is arranged perpendicular to a primary plane of the
first substrate. In specific embodiments, an outlet micro-
channel is arranged perpendicular to a primary plane of the
first substrate. In certain embodiments of the method, an
inlet microchannel is in direct fluid communication with a
nanochannel. In particular embodiments, an outlet micro-
channel is in direct fluid communication with a nanochan-
nel.
In certain embodiments of the method, the first substrate
comprises a silicon-on-insulator wafer comprising an inter-
nal oxide layer. In particular embodiments, the inlet and
outlet microchannels are patterned using a photolithography
process. In certain embodiments, forming the plurality of
inlet microchannels comprises etching material from the first
substrate, and the etching is terminated at the internal oxide
T
layer. In particular embodiments of the method, forming a
plurality of inlet macrochannels comprises etching material
from a back side of the first substrate, and the etching is
terminated at the internal oxide layer.
5 In certain embodiments the removal of the internal oxide
layer after etching material to form the inlet microchannel
and inlet macrochannels opens a pathway between the inlet
microchannels and inlet macrochannels. In particular
embodiments of the method, each nanochannel is between
io approximately one and ten nanometers deep, between
approximately ten and twenty nanometers deep, between
approximately twenty and thirty nanometers deep, between
approximately thirty and forty nanometers deep, or between
approximately forty and two hundred nanometers deep.
15 In certain embodiments of the method, the first sacrificial
material can be subsequently removed by selective etching.
In particular embodiments, the first sacrificial material is
tungsten. In specific embodiments, the second sacrificial
material can be subsequently removed by selective etching.
20 In certain embodiments of the method, the second sacrificial
material is selected from the group consisting of: tungsten,
copper, doped glass, and undoped glass. In particular
embodiments, the second sacrificial material is filled into the
plurality of inlet microchannels so that the second sacrificial
25 material extends above the top of the inlet microchannels
and is planarized by chemical-mechanical planarization
(CMP).
In particular embodiments of the method, the capping
layer is selected from silicon nitride, silicon oxide, silicon
30 carbonitride, silicon carbide, and silicon. In certain embodi-
ments, the capping layer comprises multiple depositions of
materials comprising tensile and compressive stresses such
that the net capping layer stress is tensile. In certain embodi-
ments of the method, the capping layer is between approxi-
35 mately 0.5 and 1.0 microns thick, between approximately
1.0 and 2.0 microns thick, between approximately 2.0 and
4.0 microns thick, or between approximately 4.0 and 10.0
microns thick. In specific embodiments, the capping layer is
greater than 10.0 microns thick.
40 Particular embodiments comprise a method of fabricating
a nanochannel delivery device, where the method com-
prises: providing a first substrate; forming a plurality of
nanochannels on a first side of the first substrate; filling in
the plurality of nanochannels with a sacrificial material;
45 coupling an initial capping layer to the first side of the first
substrate; forming a plurality of inlet microchannels in the
capping layer; preparing a second substrate with a bonding
layer; coupling the second substrate to a second side of the
first substrate; removing a first portion of the second sub-
50 strate; providing an additional capping layer to the second
substrate; forming a plurality of outlet microchannels in the
second substrate; and removing the sacrificial material to
open the plurality of nanochannels.
In certain embodiments of the method, the second sub-
55 strate comprises a release layer, and the release layer can be
selectively removed to cause separation of the second sub-
strate from the first substrate. In particular embodiments of
the method, an outlet microchannel is in direct fluid com-
munication with the a nanochannel. In certain embodiments,
60 the first substrate comprises a silicon-on-insulator wafer
comprising an internal oxide layer. In specific embodiments,
forming the plurality of inlet microchannels comprises etch-
ing material from the capping layer, and the etching is
terminated at the internal oxide layer.
65 In certain embodiments, forming a plurality of inlet
macrochannels comprises etching material from a back side
of the first substrate, and the etching is terminated at the
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internal oxide layer. In particular embodiments, the removal
of the internal oxide layer after etching material to form the
inlet microchannel and inlet macrochannels opens a pathway
between the inlet microchannels and inlet macrochannels.
In certain embodiments, each nanochannel is formed
between approximately one and ten nanometers deep,
between approximately ten and twenty nanometers deep,
between approximately twenty and thirty nanometers deep,
between approximately thirty and forty nanometers deep, or
between approximately forty and two hundred nanometers
deep.
In particular embodiments, the sacrificial material can be
subsequently removed by selective etching. In specific
embodiments, the sacrificial material is tungsten. In certain
embodiments, the initial capping layer is silicon nitride
deposited by plasma enhanced chemical vapor deposition. In
certain embodiments of the method, the initial capping layer
is between approximately 0.01 and 0.5 microns thick,
between approximately 0.5 and 1.0 microns thick, between
approximately 1.0 and 2.0 microns thick, between approxi-
mately 2.0 and 4.0 microns thick, or between approximately
4.0 and 10.0 microns thick. In specific embodiments of the
method, the initial capping layer is greater than 10.0 microns
thick. In certain embodiments of the method, the initial
capping layer is selected from silicon nitride, silicon oxide,
silicon carbonitride, silicon carbide, and silicon. In particu-
lar embodiments, the initial capping layer comprises mul-
tiple depositions of materials comprising tensile and com-
pressive stresses such that the net capping layer stress is
tensile. In certain embodiments of the method, the bonding
layer is selected from the group consisting of benzocy-
clobutene, silicon oxide, copper, doped glass, gold and gold
alloys.
In certain embodiments, the method of coupling the
second substrate to the first substrate is selected from the
group consisting of anodic bonding, fusion bonding, and
then nocompression bonding.
Particular embodiments include a nanochannel delivery
device comprising: a plurality of inlet microchannels, where
each of the inlet microchannels has a length, a width, and a
depth, and where the inlet microchannel length is greater
than the inlet microchannel width and depth; a plurality of
outlet microchannels, where each of the outlet microchan-
nels has a length, a width, and a depth; and a plurality of
nanochannels in fluid communication with the plurality of
inlet microchannels and outlet microchannels. In certain
embodiments, the plurality of inlet microchannels are
arranged so that the inlet microchannel width and depth
define a first plane that is parallel to the primary plane of the
nanochannel delivery device; and the plurality of outlet
micro channels are arranged so that the outlet micro channel
width and depth define a second plane that is parallel to the
primary plane of the nanochannel delivery device.
Particular embodiments include a method of treating a
condition of a person, the method comprising: providing a
nanochannel delivery device as described herein; providing
a reservoir in fluid communication with the nanochannel
delivery device; providing a substance in the reservoir,
where the substance is configured to treat the condition; and
administering the substance to the person via the nanochan-
nel delivery device. In particular embodiments of the
method, the substance is selected from the group consisting
of: leuprolide, letrozole, laptinib, buprenorphine, interferon,
and zidovudine. In certain embodiments, the condition is
selected from the group consisting of: prostate cancer, breast
cancer, opiate dependencey, giant cell angioblastoma and
HIV. In particular embodiments of the method, administer-
8
ing the substance to the person via the nanochannel delivery
device comprises subcutaneously inserting the nanochannel
delivery device into the person.
In the following, the term "coupled" is defined as con-
5 nected, although not necessarily directly, and not necessarily
mechanically.
The use of the word "a" or "an" when used in conjunction
with the term "comprising" in the claims and/or the speci-
fication may mean "one," but it is also consistent with the
10 meaning of "one or more" or "at least one." The term
"about" means, in general, the stated value plus or minus
5%. The use of the term "or" in the claims is used to mean
"and/or" unless explicitly indicated to refer to alternatives
only or the alternative are mutually exclusive, although the
15 disclosure supports a definition that refers to only alterna-
tives and "and/or."
The terms "comprise" (and any form of comprise, such as
"comprises" and "comprising"), "have" (and any form of
have, such as "has" and "having"), "include" (and any form
20 of include, such as "includes" and "including") and "con-
tain" (and any form of contain, such as "contains" and
"containing") are open-ended linking verbs. As a result, a
method or device that "comprises," "has," "includes" or
"contains" one or more steps or elements, possesses those
25 one or more steps or elements, but is not limited to possess-
ing only those one or more elements. Likewise, a step of a
method or an element of a device that "comprises," "has,"
"includes" or "contains" one or more features, possesses
those one or more features, but is not limited to possessing
30 only those one or more features. Furthermore, a device or
structure that is configured in a certain way is configured in
at least that way, but may also be configured in ways that are
not listed.
The term "inlet microchannel" is defined as a microchan-
35 nel through which a molecule travels prior to entering a
nanochannel in a nanochanneled delivery device.
The term "outlet microchannel" is defined as a micro-
channel through which a molecule travels immediately prior
to exiting a nanochanneled delivery device.
40 The term "nanochannel" is defined as a channel with a
cross-section having at least one dimension (e.g. height,
width, diameter, etc.) that is less than 200 mu.
The term "macrochannel" is defined as a channel with a
cross-section having a maximum dimension (e.g. height,
45 width, diameter, etc.) that is greater than about 10 µm.
Other objects, features and advantages of the present
invention will become apparent from the following detailed
description. It should be understood, however, that the
detailed description and the specific examples, while indi-
50 cating specific embodiments of the invention, are given by
way of illustration only, since various changes and modifi-
cations within the spirit and scope of the invention will be
apparent to those skilled in the art from this detailed descrip-
tion.
55
BRIEF DESCRIPTION OF THE FIGURES
FIGS. 1A-1J are schematic views of a manufacturing
process according to an exemplary embodiment.
60 FIGS. 2A-2E are perspective views of a first portion of a
nanochannel delivery device during the manufacturing pro-
cess.
FIGS. 3A-3F are perspective views of a second portion of
a nanochannel delivery device during the manufacturing
65 process.
FIG. 3G is a partial perspective view of a nanochannel
delivery device with representative dimensions labeled.
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FIG. 4A-4L are schematic views of a manufacturing
process according to an exemplary embodiment.
FIGS. 5A-5H are schematic cross-section views of a
nanochannel delivery device during the manufacturing pro-
cess according to an exemplary embodiment.
FIGS. 6A-6J are schematic views of a manufacturing
process according to an exemplary embodiment.
FIG. 7 is a cross-sectional side view of a schematic of an
exemplary embodiment of a nanochannel delivery device.
FIGS. 8A-8I are schematic views of a manufacturing
process according to an exemplary embodiment.
FIGS. 8J-8P are orthogonal and perspective views of
exemplary embodiments during various stages of the manu-
facturing process.
FIG. 9 is a perspective view of a nanochannel delivery
device according to an exemplary embodiment.
FIG. 10 is a cross-sectional side view of a schematic of an
exemplary embodiment of a nanochannel delivery device.
FIG. 11 is a scanning electron microscope image of a
portion of a nanochannel delivery device according to an
exemplary embodiment.
FIG. 12 is an optical image of a bonded wafer of a
nanochannel delivery device according to an exemplary
embodiment.
FIG. 13 is an optical image of a front surface of a
nanochannel delivery device according to an exemplary
embodiment after polishing.
FIG. 14 is a scanning electron microscope image of a
portion of a nanochannel delivery device according to an
exemplary embodiment.
FIG. 15 is an optical image of a portion of a nanochannel
delivery device according to an exemplary embodiment after
polishing.
FIG. 16 is scanning electron microscope image of a
portion of a nanochannel delivery device according to an
exemplary embodiment.
FIG. 17 is scanning electron microscope image of a
portion of a nanochannel delivery device according to an
exemplary embodiment.
FIG. 18 is a table of materials that may be used in
exemplary embodiments of manufacturing processes.
FIG. 19 is an exploded perspective view of a capsule and
a nanochannel delivery device according to an exemplary
embodiment.
FIG. 20 is an assembled perspective view of the embodi-
ment of FIG. 19.
FIG. 21 is an assembled perspective view of a capsule
according to an exemplary embodiment.
FIG. 22 is an exploded perspective view of the embodi-
ment of FIG. 21.
FIG. 23 is an exploded perspective view of a capsule and
a nanochannel delivery device according to an exemplary
embodiment.
FIG. 24 is an exploded perspective view of a capsule and
a nanochannel delivery device according to an exemplary
embodiment.
FIG. 25 is an assembled perspective view of a capsule
according to an exemplary embodiment.
FIG. 26 is an exploded perspective view of the embodi-
ment of FIG. 25.
FIG. 27 is an assembled perspective view of a capsule
according to an exemplary embodiment.
FIG. 28 is an exploded perspective view of the embodi-
ment of FIG. 27.
FIG. 29 is a perspective view of a capsule according to an
exemplary embodiment.
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FIG. 30 is a perspective view of a capsule according to an
exemplary embodiment in an installed location.
FIG. 31 is a perspective view and a section view of a
capsule according to an exemplary embodiment.
5
DETAILED DESCRIPTION OF ILLUSTRATIVE
EMBODIMENTS
Protocol 1: Bonded Capping Layer
10
FIGS. la-1j, 2A-2E, and 3A-3G provide illustrations of
steps performed in an exemplary first method of manufac-
turing a nanochannel delivery device. Specific dimensions
are provided for purposes of illustration only, and it is
15 understood that other exemplary embodiments may com-
prise different dimensions.
In one exemplary embodiment manufactured according to
this protocol, the top layer is a cover of a 5µm thick
evaporated glass layer and the bottom wafer is a 4 inch SOI
20 wafer with a 30 µm device layer, and a 500 µm bulk layer,
so that the supporting layer under the nanochannels has 30
µm thickness. In this exemplary structure, the inlet and
outlet microchannels are 5µm by 5µm, and the in-plane
dimension of each nanochannel is 5µm by 5µm. The space
25 between adjacent openings (e.g., the distance between adja-
cent nanochannels) is 2µm. The inlet macrochannel under
the support network is approximately 200 µm by 200 µm up
through the 500 µm thick bulk layer.
A general overview of this method of manufacturing will
30 first be presented, followed by a more detailed discussion of
the features comprised in the nanochannel delivery device.
In this embodiment, fabrication of the nanochannel delivery
device does not utilize chemical mechanical polishing
(CMP), and the microfabrication protocol comprises the
35 following steps. Starting with a SOI (silicon on insulator)
wafer (see FIG. 2A), a hard mask layer such as silicon
nitride film or LTO (low temperature oxidation) film that
will protect underneath silicon during thermal oxidation
process is deposited. If silicon nitride is used, a silicon
4o dioxide pad layer may be deposited before nitride deposi-
tion. As an alternative, the bottom substrate can also be a
silicon wafer instead of SOI if the etching process rates are
well characterized. In this case, the etching depth is con-
trolled by timing.
45 The nanochannel areas can then be patterned on the mask
layer using photolithography process. (see FIGS. 1(a) and
213), and the mask materials on nanochannel areas are
selectively removed but do not affect underneath silicon. A
combination of dry etching, and short time wet etching may
5o be applied for this purpose. Then a silicon dioxide film (with
a thickness that is well-controlled) can be deposited on bare
silicon area by thermal oxidation. In this embodiment, the
thickness of the oxidation layer is used to define the height
of nanochannels, and the mask layer is stripped.
55 A mask layer suitable for deep silicon etching can then be
deposited. The mask layer should be able to be patterned,
and have a high selectivity to silicon during deep silicon
etching process. Depending on the technique for deep sili-
con etching, a layer of silicon oxide, photoresist, or metal
60 film may be used.
In this embodiment, the inlet microchannels are patterned
on the mask layer, and the inlet microchannels are etched
down to the oxide layer of the SOI wafer by deep RIE
(Reactive Ion Etch) or ICP (Inductive Coupled Plasma)
65 technique, as shown FIGS. 1(b) and 2C. If a silicon wafer is
used, the etching depth is determined by etching rate and
time.
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The inlet macrochannels (the large openings from the
back) are laid out and etched to the oxide layer of SOI wafer,
as shown in FIGS. 1(c) and 2D, and the exposed oxide areas
are cleaned by HE solution. (see FIGS. 1(d) and 2E). To
fabricate the top cover of the nanochannel delivery devices
in this embodiment, starting with a support wafer (e.g., a
silicon wafer), a sacrificial layer is deposited. (see FIGS.
1(e), 1(f) and 3A). This sacrificial layer (e.g., indium tin
oxide (ITO)), is selected so that it can be removed in a
solution that is safe for silicon and top cover materials.
The top cover of the nanochannel delivery devices is
deposited on the sacrificial layer (see FIGS. 1(g) and 313),
and the outlets are patterned on the structure, as shown in
FIGS. 1(h) and 3C). As an alternative, a lift-off technique
may be applied for the cases of sputtered glass or e-beam
evaporated glass. The materials may be any suitable mate-
rial, e.g. spin-on-glass, sputtered glass, e-beam evaporated
glass, ITO-glass sandwich, silicon, polymer, etc. The mate-
rials may include glass and glass materials known to those
skilled in the art to bond to silicon by specific means, e.g.,
anodic bonding or fusion bonding. The materials should be
able to bond to silicon by certain means. For instance of
glass, anodic bonding can be applied. A spin-on-glass layer
may also applicable. Depending on the surface quality, a
planarization process may be needed.
The structure wafer and the top cover are bonded together
by a technique such as anodic bonding or Si Si direct
bonding or intermediate layer aided bonding, as shown in
FIGS. 1(c), 3D, and 3E, and the support wafer of top cover
is removed (as shown in FIGS. 1(j) and 3F). Finally, the
individual nanochannel delivery devices are obtained by
dicing the wafer, and cleaning.
In another exemplary embodiment manufactured accord-
ing to this protocol, while keeping the bottom silicon sub-
strate is the same 4 inch SOI wafer with a 30 µm device layer
and a 500 µm bulk layer as that mentioned in above
embodiment, the top layer is a 10 µm thick glass film. The
10 um thick glass film is manufactured by thinning a thicker
glass layer. To make this thin film, a 100 um to 500 um thick
glass wafer is bonded to the structural silicon substrate. A
planarization technique such as backgrinding, or lapping, or
CMP, or chemical etching, or dry etching is then applied to
thin the glass layer until the designed thickness such 10 um
is reached. The outlets are then patterned on the thinned
glass film, and etched down to the underneath silicon surface
to open the outlets. In this exemplary structure, the inlet and
outlet microchannels are 5µm by 5µm, and the in-plane
dimension of each nanochannel is 5µm by 5µm. The space
between adjacent openings (e.g., the distance between adja-
cent nanochannels) is 2µm. The inlet macrochannel under
the support network is 200 µm by 200 µm up through the 500
µm thick bulk layer.
Referring specifically now to FIGS. 2A-2E and 3A-3F, a
more detailed view of the features of nanochannel delivery
device 100 is provided. Referring initially to FIG. 2A, an
SOI wafer 10 comprises a top layer 15 over a substrate 20
and separated by an oxide layer 35. As shown in FIG. 213,
a series of nanochannels 25 are formed using a pattern mask
in top layer 15. One or more inlet microchannels 30 is
formed using a pattern mask in each nanochannel 25, as
shown in FIG. 2C, exposing an oxide layer 35 between the
substrate 20 and the top layer 15. For purposes of clarity not
all features, for example inlet microchannels 30, are labeled
in the figures.
As shown in FIG. 2D, a portion of substrate 20 is removed
using a pattern mask from below the oxide layer 35. Oxide
layer 35 is then removed (as shown in FIG. 2E), and inlet
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microchannels 30 are formed to allow passage of material
through the substrate 20 and top layer 15. At this stage, the
lower portion 40 of nanochannel delivery device 100 is
complete.
5 Referring now to FIGS. 3A-3F, the fabrication of the
upper portion 45 of nanochannel delivery device 100 begins
with a sacrificial layer 50 deposited on a support substrate
55. In addition, an additional layer 60 (e.g., spin-on-glass,
sputtered glass, e-beam evaporated glass, ITO-glass sand-
io wich, silicon, polymer, etc.) may be used in processes
utilizing a lift-off technique, as shown in FIG. 3B. Exit
microchannels 70 are formed in sacrificial layer (and addi-
tional layer 60, if utilized) as shown in FIG. 3C.
At this stage, upper portion 45 is ready to be bonded to
15 lower portion 40 of nanochannel delivery device 100. It is
understood, the designations "upper" and "lower" are used
only for purposes of clarification in the description of the
figures, and do not dictate the relationship of components
during use of the device. As shown in FIGS. 3D and 3E,
20 upper portion 45 and lower portion 40 are bonded together
(through, e.g., anodic bonding or Si Si direct bonding or
intermediate layer aided bonding). Support substrate 55 is
removed from upper portion 45, and nanochannel delivery
device 100 is completed, as shown in FIGS. 3F and 3G. The
25 embodiment shown in FIG. 3G comprises optional tapered
surfaces in the transitions between outlet microchannels 70
and nanochannels 25, as well as between nanochannels 25
and inlet microchannels 30.
As shown in FIG. 3G, nanochannels 25 lie in a plane
30 parallel to the primary plane of nanochannel delivery device
100 (e.g., the plane defined by the larger dimensions [in this
example, L and W] of nanochannel delivery device 100).
Such a configuration allows for the length of nanochannel 25
(e.g., approximately the distance between adjacent outlet 70
35 and inlet 30) and the height and width of the nanochannel to
be varied without varying the length L, width W, and
thickness T of nanochannel delivery device 100. The thick-
ness T of nanochannel delivery device 100 can therefore be
based on other criteria (such as mechanical integrity) rather
40 than the need to control the flow of a substance being
delivered via nanochannel delivery device 100.
The embodiments shown in FIGS. 3A-3G also provide for
each outlet 70 to be in fluid communication with any inlet 30
via a single nanochannel 25. Such a configuration can
45 provide for greater control over the diffusion of a substance
being delivered via nanochannel delivery device 100. For
example, the diffusion rate through nanochannel delivery
device 100 is more closely related to the dimensions of
nanochannel 25, as compared to configurations that have
5o numerous nanochannels in fluid communication with a
single extended inlet. In such configurations, the inlet (rather
than the nanochannel) may become a restriction on flow and
limit the ability to control the flow by varying the dimen-
sions of the nanochannel.
55 As shown in the detailed view of FIG. 3G (not to scale),
nanochannel 25 comprises a length nL, a width nW and a
height nH. Outlet microchannel 70 comprises a length oL, a
width oW, and a height oH. In addition, inlet microchannel
30 comprises a length iL, a width iW and a height iH. As
60 shown in FIG. 3G, the "length" of each channel is measured
along the path that a molecule would travel as it moves from
inlet microchannel 30, through nanochannel 25, and out
through outlet microchannel 70. In certain embodiments
oL=4 um, oW-5 um, off-5 um while nH=50 mu, nW=4 um,
65 and nL-5 um and oL=30 um, oW-5 um, off-5 um.
In certain embodiments, the ratio of oL/nL or iL/nL can be
0. 1, 0. 2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.1, 1.2, 1.3, 1.4, 1.5,
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1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9,
3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3,
4.4, 4.5, 4.6, 4.7, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8,
5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2,
7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 5
8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10,
20, 30, 40 50, 60, 70, 80, 90, or 100.
Protocol 2: Multilayered Structure with Bonded Capping
Layer
In a second embodiment, a multilayered nanochannel io
structure can be fabricated by modifying the above-de-
scribed protocol 1. This embodiment comprises the follow-
ing steps. Starting with a SOI (silicon on insulator) silicon
wafer, a silicon dioxide layer (with a thickness that is
well-controlled) is deposited by thermal oxidation. The 15
thickness of the oxidation layer can be used to define the
height of nanochannels. As an alternative, the bottom sub-
strate can also be silicon wafer instead of SOI if the etching
process rates are well characterized. The nanochannel areas
can be patterned on the oxide layer using photolithography 20
process.
The silicon oxide on non-nanochannel areas can be selec-
tively removed but not affect the oxide on nanochannel area.
(See FIG. 4(a)). A polysilicon structure layer can be depos-
ited on the top of oxide nanochannel spacing layer. (see FIG. 25
4(b)). A second defined thickness oxide layer can be depos-
ited again, and the nanochannel areas can be patterned on the
oxide layer using photolithography process. The silicon
oxide on non-nanochannel areas can be selectively removed
but do not affect the oxide on nanochannel area. (See FIG. 30
4(c)). This process finishes the second layer of nanochan-
nels. The previous two steps can be repeated to achieve
desired number of layers.
As an alternative to the previous steps, the silicon oxide
nanochannel spacing layer and multilayer structure layer 35
may also use other materials. For example, an aluminum
film as nanochannel spacing layer, and evaporated glass film
as multilayer structure layers.
A first mask layer suitable for deep silicon etching can be
deposited. The mask layer should be able to be patterned, 40
and have high selectivity to silicon during deep silicon
etching process. Depending on the technique for deep sili-
con etching, a layer of silicon oxide, photoresist, or metal
film may be used.
The inlet microchannels are patterned on the first mask 45
layer, and a second mask layer is deposited on the top of first
mask layer. The inlet microchannels are patterned on the
both first and second mask layers. The outlet microchannels
are etched down to a certain depth close to oxide layer of the
SOI wafer, and the second mask layer is stripped to expose 50
the first mask layer. The outlet microchannel is etched
through multiple layers of the nanochannel spacing layer
and structure layer. A combination of wet etching and DRIE
may be applied. This will also etch the inlet down to the
insulator layer of SOI wafer. (See FIG. 4(i)). If a silicon 55
wafer is used, the etching depth is determined by etching
rate and time. Then the inlet macrochannels on the back are
laid out and etched to the oxide layer of SOI wafer (see FIG.
4(e)), and the oxide on the exposed areas is cleaned. (See
FIG. 4(f)). 60
To fabricate the top cover of the nanochannel delivery
devices, starting with a support wafer (e.g., a silicon wafer),
a sacrificial layer is deposited. (See FIG. 4(h)). This sacri-
ficial layer is selected so that it can be removed in a solution
that is safe for silicon and top cover materials. The top cover 65
of the nanochannel delivery device is deposited on the
supporting wafer and the inlet microchannels are etched. A
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lift off technique may be applied for certain cases. (See FIG.
4(i j)). The materials may include, for example, spin-on-
glass, sputtered glass, e-beam evaporated glass, ITO-glass
sandwich, silicon, etc. The materials should be able to bond
to silicon by some means. For instance, a transparent glass
layer can be deposited by e-beam evaporation. A spin-on-
glass layer may also usable. Depending on the surface
quality, a planarization may be needed. The structure wafer
from the previous step and the top cover can be bonded
together by a technique such as anodic bonding or Si Si
direct bonding or intermediate layer aid bonding. (See FIG.
4(k)). The support wafer of top cover can be removed (See
FIG. 4(1)), and the devices obtained by dicing the wafer and
cleaning.
Protocol 3: Monolithically Fabricated Capping Layer
As a third embodiment, a nanochannel structure can be
fabricated monolithically (e.g., without bonding) and
optionally utilizing CMP in the process. This exemplary
microfabrication protocol comprises the following steps as
shown in FIGS. 5A-5H.
Specific dimensions are provided for purposes of illus-
tration only, and it is understood that other exemplary
embodiments may comprise different dimensions. In this
embodiment, the top layer is approximately 2µm of depos-
ited silicon nitride. This embodiment also comprises a
bottom wafer that is a 8 inch SOI wafer with a 30 µm device
layer, and a 725 µm bulk layer, so that the supporting layer
under the nanochannels has 30 µm thickness. In this exem-
plary structure, the openings for the inlet and outlet micro-
channels are 3µm by 5µm, and the in-plane dimension of
each nanochannel is 3µm by 5µm. The space between
adjacent microchannel openings is 2µm. As in previously-
described embodiments, the inlet macrochannel under the
support network is approximately 200 µm by 200 µm up
through the 725 µm thick bulk layer.
Starting with an SOI (silicon on insulator) wafer 210, a
nanochannel spacing layer 220 (with a thickness that is well
controlled, for example, ±5% over the relevant portion of
SOI wafer 210) is deposited. The thickness of spacing layer
220 can be used to define the height of the nanochannels.
This spacing layer 220 is a sacrificial layer, and the material
will be removed in a subsequent step, so the silicon surface
immediately under it is the "floor" of the eventually formed
nanochannels. The spacing material should have a high wet
etch selectivity to other materials in the nanochannel deliv-
ery device (nDD). As an example, a thin film of tungsten,
germanium, or silicon oxide can be used for the nanochannel
spacing layer 220.
As shown in FIG. 5A, a capping layer 230 is deposited
over the nanochannel spacing layer 220. Capping layer 230
will ultimately be the "ceiling" of the nanochannels. Silicon
nitride, silicon oxide, silicon carbide, or other material
which has a high etch selectivity to the material for spacing
layer 220 may be used for capping layer 230.
A mask layer (not shown) suitable for deep reactive-ion
etching (DRIE) is deposited, and the inlet microchannels
240 are patterned on the mask layer using photolithography.
As shown in FIG. 513, the DRIE process(es) etch micro-
channels 240 through the capping layer 230 and spacing
layer 220 and silicon down to the buried oxide layer 250 of
SOI wafer 210. The mask layer can then be removed.
As shown in FIG. 5C, inlet microchannels 240 are filled
with a fill material 260 that can be polished by CMP or
etched. Non-limiting examples of fill material 260 include
copper, tungsten, polysilicon, or phosphosilicate glass, each
deposited by techniques known in the art. Fill material 260
should have a wet etch with high selectivity to silicon and
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the material of capping layer 230. In this exemplary embodi-
ment, fill material 260 only needs to fill in the top of inlet
microchannels 240. A CMP or etch back process can be used
to remove the excess fill material 260 that extends above or
outside of inlet microchannels 240. The surface of the
remaining fill material 260 should be above the level of
spacing layer 220.
Referring now to FIG. 5D, additional material may be
deposited onto capping layer 230. The areas of capping layer
230 and spacing layer 220 above and between the inlet
microchannels 240 can be patterned using a photolithogra-
phy process. The spacing layer 220 and capping layer 230
outside of the inlet nanochannels 240 (e.g., regions 221 and
231) can be etched to or slightly below the silicon surface.
Referring now to FIG. 5E, a final capping layer 270 is
deposited over the entire surface of wafer 210 to provide
structural rigidity and seal the sidewalls of the nanochannel
areas. Using a photolithography process, outlet microchan-
nels 280 can be patterned and etched through capping layers
230, 270 and optionally through spacing layer 220 into
silicon 210 for additional process latitude. As shown in FIG.
5F, a protective layer 275 is deposited over capping layer
270 and outlet microchannels 280.
Referring now to FIG. 5G, wafer 210 can then be inverted
and large openings for inlet macrochannels 245 on the back
of wafer 210 can be formed by DRIE down to the buried
oxide layer 250 of wafer 210. As shown in FIG. 5H,
sacrificial and protective layers used during processing (e.g.
spacing layer 220, fill material 260, capping layer 270, and
portions of oxide layer 250) are removed by appropriate
processes known in the art. As shown in FIG. 5H, when
spacing layer 220 is removed, nanochannels 205 are formed.
The wafers can then be diced to get individual nanochannel
delivery devices.
As illustrated in this embodiment, nanochannels 205 are
in direct fluid communication with inlet microchannels 240
and outlet microchannels 280. Specifically, inlet microchan-
nels 240 and nanochannels 205 are directly connected so
that a fluid exiting an inlet microchannel will immediately
enter the nanochannel without flowing through an intenne-
diate body.
As a variant of this protocol, and in analogy to protocol
2 above, a multilayered structure can be built by repeated
application of the monolithic top layer process. A plurality
of capping layer 230 and spacing layer 220 pairs can be
deposited. The inlet microchannels can be etched through all
layers down to the buried oxide and filled with fill material
260 and polished as above. The final capping layer 270 can
be applied and outlet microchannels 280 etched as above.
Protocol 4: Varying the Length of Nanochannels
In certain embodiments, Protocol 1 can be modified to
make a nanochannel delivery device with different a nano-
channel length while keep other features unchanged. An
exemplary microfabrication protocol comprises the follow-
ing steps.
Starting with a SOI (silicon on insulator) wafer, a hard
mask layer such as silicon nitride film or LTO (low tem-
perature oxidation) film that will protect the underneath
silicon during thermal oxidation process is deposited. If
silicon nitride is used, a silicon dioxide pad layer may be
deposited before nitride deposition. As an alternative, the
bottom substrate can also be silicon wafer instead of SOI if
the etching process rates are well characterized.
The nanochannel areas can be patterned on the mask layer
using photolithography process. (See FIG. 6(a)), and the
mask materials on nanochannel areas are selectively
removed but do not affect underneath silicon. A combination
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of dry etching, and short time wet etching may be applied for
this purpose. A silicon dioxide film (with a well-controlled
thickness) is deposited on the bare silicon area by thermal
oxidation. The thickness of the oxidation layer defines the
5 height of nanochannels, and the mask layer and oxide is
stripped.
A mask layer suitable for potassium hydroxide (KOH)
wet etching is deposited, such as silicon nitride. A new mask
is designed to lay-out both inlet microchannels and outlet
io microchannels on the same layer, and the nanochannel
length is defined by the spacing between adjacent inlet and
outlet microchannels. The mask layer is patterned using the
new mask by standard photolithography process. The mask
materials on open areas are selectively removed. Then a
15 KOH wet etching is applied to form openings with the slope
wall, and the mask layer is stripped. (See FIG. 6(b)).
A mask layer suitable for deep silicon etching can be
deposited. The mask layer should be able to be patterned,
and have a high selectivity to silicon during deep silicon
20 etching process. Depending on the technique for deep sili-
con etching, a layer of silicon oxide, photoresist, metal film,
or other suitable material may be used.
The outlet microchannels are patterned on the mask layer
and the outlet micro channels are etched down to the oxide
25 layer of the SOI wafer by a suitable technique, for example
a deep RIE or ICP technique. (See FIG. 6(c)). If a silicon
wafer is used, the etching depth can be determined by
etching rate and time.
The inlet macrochannels from the back are laid out and
30 etched to the oxide layer of the SOI wafer, and the exposed
oxide areas are cleaned by HF solution. (See FIG. 6(d)). To
fabricate the top cover of the nanochannel delivery devices,
starting with a support wafer (e.g., silicon wafer), a sacri-
ficial layer is deposited. (See FIG. 6(e, ff). This sacrificial
35 layer (e.g. ITO), is selected so that it can be removed in a
solution that is safe for silicon and top cover materials.
The top cover of the nanochannel delivery devices is
deposited on the sacrificial layer. (See FIG. 6(g)), and the
outlets are patterned on the structure. (See FIG. 6(h)). As an
4o alternative, a lift-off technique may be applied for the cases
of sputtered glass or e-beam evaporated glass. In certain
embodiments, the materials may be spin-on-glass, sputtered
glass, e-beam evaporated glass, ITO-glass sandwich, silicon,
polymer, etc. The materials should be able to bond to silicon
45 by certain means. For instance of glass, anodic bonding can
be applied. A spin-on-glass layer may also applicable.
Depending on the surface quality, a planarization process
may be needed.
The structure wafer from step (6) and the top cover can be
5o bonded together by a technique such as anodic bonding or
Si Si direct bonding or intermediate layer aided bonding.
(See FIG. 6(i)). The support wafer of top cover is removed
(See FIG. 6(j)), and the devices are obtained by dicing the
wafer, and cleaning.
55 If the preferred length of nanochannel is less than 500 mu,
a nanofabrication technique such as e-beam or nanoimprint
may be applied. Isotropic silicon etching technique may also
be applied. A schematic structure view of a short nanochan-
nel delivery device is shown in FIG. 7. As shown in FIG. 7,
60 inlet microchannel 340 has a portion 341 that is flared or
tapered proximal to nanochannel 305. Similarly, outlet
microchannel 380 has a portion 381 that is flared or tapered
proximal to nanochannel 305. Nanochannel 305 is therefore
shortened as a result of portions 341 and 381.
65 Protocol 5: Hybrid Monolithic-Bonded Capping Layer
As a fifth embodiment, a nanochannel structure can be
fabricated without the use of a CMP process, while utilizing
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bonding as a non-critical step in the capping layer fabrica-
tion. This exemplary microfabrication protocol comprises
the following steps as seen in FIGS. 8A-8P.
Referring initially to FIG. 8A, starting with an SOI
(silicon on insulator) substrate wafer 410, a nanochannel
spacing layer 420 (with a thickness that is well-controlled,
for example, ±5% over the relevant portion of SOI substrate
wafer 410) is deposited. The thickness of spacing layer 420
can be used to define the height of the nanochannels. This
spacing layer 420 is a sacrificial layer, and the material will
be removed in a subsequent step, so the silicon surface
immediately under it is the "floor" of the eventually formed
nanochannels. The spacing material should have a high wet
etch selectivity to all other materials in the nanochannel
delivery device. As an example, a thin film of tungsten,
germanium, or silicon oxide can be used for nanochannel
spacing layer 420.
A capping layer 430 is deposited over nanochannel spac-
ing layer 420. Capping layer 430 will ultimately be the
"ceiling" of the nanochannels. Silicon nitride, silicon oxide,
silicon carbide, or other material which has a high wet etch
selectivity to the material for spacing layer 420 may be used
for capping layer 430. The nanochannel areas can be pat-
terned on spacing layer 420 and capping layer 430 using a
photolithography process. As shown in FIG. 813, spacing
layer 420 and capping layer 430 on non-nanochannel areas
432 and 433 are etched to or slightly below the silicon
surface of silicon wafer 410.
Referring now to FIG. 8C, additional capping material
431 is deposited, and optionally planarized by CMP to
provide a flat surface. Inlet microchannels 440 are patterned
on the mask layer (not shown) using photolithography. The
DRIE process(es) etch inlet microchannels 440 through the
capping layer 430 and spacing layer 420 and silicon down to
a buried oxide layer 450 of SOI substrate wafer 410. The
mask layer is removed and additional appropriate surface
layers useful for bonding can be deposited on this surface,
as needed.
Referring now to FIG. 8D, on another silicon substrate
(e.g. a capping wafer 411), a layer 421 (comprising, for
example, silicon nitride or silicon oxide) can be deposited.
On top of layer 421, a bonding layer 441 is deposited. The
material for bonding layer 441 can be chosen so as to adhere
well to the material on the surface of wafer 410 (e.g. capping
material 431). The material for bonding layer 441 can also
be designed so that any surface particles can be absorbed
into bonding layer 441 to prevent any delamination between
capping wafer 410 and substrate wafer 411 after bonding.
Alternatively, a highly clean process before and during
bonding can be used without this requirement. Exemplary
materials for bonding layer 441 include polymeric materials,
silicon oxide, and copper. Before the application of bonding
layer 441, optionally, a material with a very high etch rate,
"the release layer" 421, can also be applied with an addi-
tional silicon nitride or silicon oxide layer (not shown) on
top of this release layer. Layer 421 can comprise a material
with a high selectivity to other materials in the nanochannel
delivery device.
Referring now to FIG. 8E, capping wafer 411 and sub-
strate wafer 410 are then bonded onto each other. In certain
embodiments, the bonding can be polymer-silicon nitride
bond, such as Benzocyclobutene (BCB)-silicon nitride, cop-
per-copper then nocompres sion bond or oxide-to-oxide
fusion bond, each with appropriate pre- and post-bond
treatments known to those skilled in the art.
Referring now to FIG. 8F, the silicon portion of capping
wafer 411 is then removed through a suitable process, e.g.
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mechanical thinning, a chemical etch, or a combination of
both. In the case of the optionally added "release layer" 421,
the release layer can be selectively removed to cause sepa-
ration of the silicon capping wafer 411 from substrate wafer
5 410.
Referring now to FIG. 8G, using a photolithography
process, outlet microchannels 480 can be patterned and
etched through optional release layer 421, bonding layer
441, capping material 431, capping layer 430, and optionally
io through spacing layer 420 into the silicon for additional
process latitude.
Referring now to FIG. 8H, a protective capping layer 470
is deposited over the surface of substrate wafer 410. Wafer
410 (with layer 421 and bonding layer 441 from wafer 411)
15 is then inverted and inlet macrochannels 445 on the back of
wafer 410 can be formed by DRIE down to the buried oxide
layer 450 of wafer 410.
Referring now to FIG. 8I, sacrificial layers (e.g. spacing
layer 420, capping layer 470, and portions of oxide layer
20 450) are removed by appropriate processes known in the art.
As shown in FIG. 8I, when spacing layer 420 is removed,
nanochannels 405 are formed. As illustrated in this embodi-
ment, nanochannels 405 are in direct fluid communication
with inlet microchannels 440 and outlet microchannels 480.
25 Referring now to FIG. 87, a top view of the entire wafer
410 is illustrated. As shown in this view, wafer 410 (prior to
dicing) comprises several nanochannel delivery devices 400
(only one of which is identified in the figure). Wafer 410 can
be diced to separate the individual nanochannel delivery
3o devices 400 from each other. A detailed view of an indi-
vidual nanochannel delivery device 400 with exemplary
dimensions is illustrated in FIG. 8K. In this view, a plurality
of inlet macrochannels 445 are visible on one side of
nanochannel delivery device 400. This exemplary embodi-
35 ment of nanochannel delivery device 400 is approximately
6.0 mm square, and the inlet macrochannels form a gener-
ally circular shape approximately 3.6 mm in diameter. It is
understood that while wafer 410 of Protocol 5 is illustrated
in FIG. 87, other protocols will also yield wafers that
40 comprise multiple nanochannel delivery devices, and can be
diced or separated into the individual devices. It is also
understood that other exemplary embodiments may com-
prise different dimensions than those shown in FIG. 8K. In
some embodiments, the wafer 410 may remain whole,
45 effectively forming a nanochannel delivery device with
dimensions similar to that of a silicon wafer, for example,
approximately 500 to 750 micrometers in thickness and 100,
150, 200, 300, 450, or 675 mm in diameter.
For example, referring to FIGS. 8L and 8M a nanochannel
5o delivery device 500 is shown comprising a body 501 that is
substantially planar and has a rectangular shape with a
thickness "T", a length "L" that is 4 mm and a width "W"
that is 3 mm. The thickness "T" may be varied, but in certain
embodiments is approximately 550-700 µm, and is less than
55 either length L or width W. Length L and width W define the
primary plane of nanochannel delivery device 500. As
shown in the figures, body 501 has an inlet surface 502 on
one side and an outlet surface 503 on the opposite side. Inlet
surface 502 and outlet surface 503 are generally parallel to
60 each other and parallel to the primary plane of nanochannel
delivery device 500. Visible in FIG. 8M are a plurality of
inlet macrochannels 545 (only one of which is identified in
the figure). FIG. 8N provides a perspective view of a partial
cross-section of nanochannel delivery device 500 taken
65 along line 8N-8N in FIG. 8M. The portion illustrated in FIG.
8N comprises a single inlet macrochannel 545 and multiple
inlet microchannels 540 and outlet microchannels 580. As
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shown in FIGS. 8L-8N, inlet microchannels 540 and outlet
microchannels 580 are formed so that individual inlet and
outlet microchannels are perpendicular to the primary plane
of nanochannel delivery device 500 (e.g., the length of the
microchannels is measured along a line that is perpendicular
to the primary plane of the device). In addition, the plurality
of inlet microchannels 540 and outlet microchannels 580
form overlapping arrays so that individual inlet microchan-
nels 580 are distributed between individual outlet micro-
channels 580, and vice versa. Referring now to FIG. 8 As
shown in the detailed view of FIG. 80, each nanochannel
505 is in direct fluid communication with an inlet micro-
channel 540 and an outlet microchannel 580.
Referring now to FIG. 8P, a detailed section view of a
section of nanochannel delivery device 500 is illustrated. In
this view, three inlet nanochannels 540 are visible, along
with a pair of outlet microchannels 580 and a pair of
nanochannels 505. As shown, nanochannel 505 comprises
an inlet end 506 and an outlet end 507. In this embodiment,
a first linear axis 508 extends between inlet end 506 and inlet
surface 502. Also visible in FIG. 8P, a second linear axis 509
extends between outlet end 507 and outlet surface 503.
Also shown in FIG. 8P, inlet microchannel 540 comprises
a primary axis 512 and outlet microchannel 580 comprises
a primary axis 511. As shown in this embodiment, primary
axis 511 and primary axis 512 are perpendicular to a plane
513 that is parallel to a substantially planar body 550 of
nanochannel delivery device 500. In FIG. 8P, only a portion
of substantially planar body 550 is shown. A complete view
of substantially planar body 550 is visible in FIGS. 8L and
8M.
Referring now to FIG. 9, specific dimensions for an
exemplary embodiment of a nanochannel delivery device
manufactured according to the above protocol are provided.
It is understood that these dimensions are illustrative of the
specific embodiment shown, and that other embodiments
may incorporate different dimensions.
Referring now to FIG. 10, a partial cross-section of
nanochannel delivery device 500 illustrates the diffusion
path 575 for a molecule passing through nanochannel deliv-
ery device 500. It is understood that nanochannel delivery
device 500 may be oriented in any direction during use. As
shown in FIG. 10, flow path 105 requires a maximum of two
changes in direction between the point where the molecule
enters nanochannel delivery device 500 and the point at
which the molecule exits nanochannel delivery device 500.
For example, the molecule enters nanochannel delivery
device 500 and is initially located within inlet macrochannel
545. The molecule then enters inlet microchannel 540. In the
embodiment shown, flow path 575 turns at a 90 degree angle
to the right as the molecule enters the nanochannel 505 that
is in direct fluid communication with inlet microchannel
540. After the molecule exits the nanochannel 505, the flow
path turns again (this time, a 90 degree turn to the left) as it
enters the outlet microchannel 580, which is also in direct
fluid communication with the nanochannel 505. Therefore,
flow path 575 requires a maximum of two changes in
direction as the molecule diffuses through nanochannel
delivery device 500. While a molecule may undergo more
than two changes in direction as it passes through nano-
channel delivery device 500, it is only required to make two
changes in direction.
Example
Protocol 1: Bonded Capping Layer
The following example is provided as an illustration of
one non-limiting embodiment of a method of manufacturing
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a nanochannel delivery device according to Protocol 1
(described above). This example is provided for illustration
purposes only and is not intended to limit the scope of the
invention described herein.
5 Processing begins with a double polished 4" SOI wafer
(available from Silicon Quest). The wafer comprises a
device layer that is 30 um thick, <100> orientation P-type,
Boron doped, and a 1-10 Ohm-cm surface resistivity, a
buried oxide layer that is 0.4 um thick and a handle layer that
io is 500 um thick, P-type, Boron doped, and 1-10 Ohm-cm
surface resistivity. The wafer was cleaned in a fresh Piranha
solution (3:1 98% sulfuric acid: 30% hydrogen peroxide,
over 100 C) for 10 min, and spun dried. A 50 nm pad oxide
layer was then thermally grown on the surface. Then a 100
15 nm low-stress nitride was deposited on the pad oxide layer
by low-pressure chemical vapor deposition (LPCVD). The 5
um wide nanochannel patterns were transferred from the
photo mask onto the silicon nitride layer by standard pho-
tolithography using an EVG 620 aligner. The exposed
20 nitride area was removed by CF4 RIE.
After the photoresist was stripped, the pad oxide was
cleaned by dipping in 1:10 HE water solution. Then the
wafer was placed in a thermal oxide furnace to grow
sacrificial oxide. The thickness of this sacrificial oxide
25 determined the height of nanochannels, i.e. height of
nanochannel-0.46 *Thickness of Oxide. In this example, a
39 nm oxide was grown for 18 nm nanochannels. Then the
nitride and oxide were removed in dilute HE solution. A 3
um thick low temperature oxide (LTO) layer was then
3o deposited on the surface by LPCVD. Then the backside of
wafer was protected by 3 um spun-on Futurrex negative
photoresist. The LTO on front side was removed in a
buffered oxide etch (BOE) solution, and the wafer was
cleaned in piranha solution.
35 A 500 nm LTO film was deposited on the wafer using
LPCVD. The 5 umx5 um inlet microchannel patterns were
transferred to the LTO film on the device side of wafer using
standard lithography on an EVG 620 aligner, and LTO were
etched using CF4 RIE. Then the 200 umx200 um inlet
40 macrochannel patterns were transferred onto the backside of
the wafer, and RIE was done.
After cleaning out the photoresist, deep silicon etching of
inlet microchannels was done using an Oerlikon DSE etcher.
The etching was stopped on the buried oxide layer. The
45 wafer was flipped over, and attached onto a handle wafer
using thermal grease (Al Technology). The 190 umx190 um
inlet macrochannels were then etched on the Oerlikon DSE
etcher, and stopped on the oxide layer. FIG. 11 shows a SEM
image of deep etched 190 um openings. The wafer was
5o detached from the handle wafer, and cleaned. The wafer was
dipped in BOE for 5 min to open the buried oxide layer, and
spun dried. Then mask LTO films on both sides of wafer
were removed in HE water solution.
A 500 um thick double side polished Pyrex 7740 glass
55 wafer was bonded onto the silicon substrate as a nanochan-
nel cap by anodic bonding using an EVG 520 bonder. The
anodic binding was performed at 800 volts, and 325° C. for
10 min. FIG. 12 shows an optical image of the bonded wafer.
The bonded wafer pair was adhered on a wafer holder using
60 wax, and backlapping was applied to thin the glass down to
30 um, and then CMP polished to a final thickness of 5-10
um (by Valley Design Corp).
FIG. 13 shows an optical image of the front surface after
polishing. The contrast indicates that nanochannels are open.
65 The 5 umx5 um outlet microchannels were formed by
CF4/Ar RIE using Ni film as mask layer. To do so, a copper
seed layer was firstly deposited on the glass surface. The 5
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umx5 um outlet microchannel patterns were transferred to
the copper film using standard lithography on an EVG 620
aligner, and were wet etched. Then Ni was electroplated
onto the patterned copper film. The CF4/Ar RIE was used to
etch the inlet microchannels into the glass film to reach the
silicon surface. After stripping the mask layer, the wafer was
cleaned, and diced using DAD321 Dicing Saw (Disco). The
fabricated devices are 6 mmx6 mm overall dimension. There
are 161 in total 190 umx190 um openings arranged in a 3.6
mm diameter circle. Each such opening is connected to 501
in total 5 umx5 um inlet channels, and the inlet channels are
connected to nanochannel and outlet channels.
Example
Protocol 3: Monolithically Fabricated Capping
Layer
The following example is provided as an illustration of
one non-limiting embodiment of a method of manufacturing
a nanochannel delivery device according to Protocol 3
(described above). This example is provided for illustration
purposes only and is not intended to limit the scope of the
invention described herein.
Processing begins with a double-side polished Silicon On
Insulator (SOI) wafer using a 690 um thick base wafer with
a top silicon layer thickness of 30 um and a buried oxide
thickness of 2 um. This wafer is cleaned with a piranha
solution (3:1 98% Sulfuric acid:30% Hydrogen peroxide,
over 100 C) to remove any organic and metal contamination.
A smooth (typically <5 A rms), uniform (typically <2%
non-uniformity,) tungsten metal layer is sputtered on this
wafer, using a physical vapor deposition (PVD) process at a
temperature of 100 C. The thickness of this tungsten layer is
selected to be the height of the nanochannel layer, for
example 5 mu.
The nanochannel space layer is then covered by a plasma
enhanced chemical vapor deposition (PECVD) silicon
nitride (" S1NI") with low stress (380 C, appropriate stoi-
chiometry), with a target thickness of 500 mu and a non-
uniformity of less than 2%. Positive resist is then spun on,
with a thickness of 2 um. The inlet microchannels are
exposed in this resist, with the sizes varying from 1 um to
over 5 um, as needed. Using this resist, the applied silicon
nitride is etched through, along with tungsten, using a
conventional C4F8 etch chemistry with appropriate plasma
powers, and other reactive and inert gases.
The etch in this process is timed to be deep enough that
it goes through the tungsten layer also, which takes a few
minutes. Another etch is performed, still using the resist as
the mask, to etch a deep via in the silicon that is deep enough
to go into the buried oxide. A 5 dep/5 etch per cycle Bosch
etch is used in this step since the etch automatically termi-
nates at, and is highly selective to, the buried oxide. A small
overetch of 10-20% of the most critical structure is provided
to compensate for the non-uniformity of the process. The
remaining resist is then removed using an oxygen plasma
and the wafers are additionally cleaned of all polymer
residues using an appropriate wet chemistry FIG. 14 pres-
ents an example of a device at this stage of process.
The next module consists of filling or capping these inlet
microchannels. This can be accomplished by plugging the
inlets with copper. A TiN barrier layer is deposited by
sputter, with a thickness of 300 A. A copper seed layer, with
a nominal thickness of about 4000 A is deposited through a
PVD sputter process. A low current (2 A, 10-15 minutes)
electroplating process is used to fill or plug the inlet micro-
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channels. The excess copper overburden is then polished
away using a pad/slurry combination, under moderate pres-
sure/speed (2-4 psi, 30-90 rpm) process. In this same pro-
cess, the TiN in the non-microchannel area (field) is also
5 completely removed. Finally, the inlet microchannel process
is hardened with a short bake anneal at 150-250 C, for about
30 minutes, and the surface is cleaned. FIG. 15 presents a top
view of the device after filling with copper.
A thin silicon nitride ("SiN2") layer of about 50 nm is
io deposited by PECVD to cap the copper. The nanochannel
lines are then exposed in resist (1.3 um) using photolithog-
raphy and the silicon nitride (S1NI as well as SiN2) layers
are etched, along with the tungsten nanochannel material,
with the etch proceeding a few tens of nanometers into the
15 silicon.
A thicker, tensile silicon nitride ("SiN3") is then depos-
ited, of a thickness of about 1-1.5 um. The tensile stress of
this layer is chosen so as to make the overall dielectric stack
slightly tensile by about 20 MPa. The outlet microchannels
20 are then exposed on a resist layer (of nominal thickness 2
um) and a further etch of all silicon nitride layers (S1NI,
SiN2, SiN3) along with the W nanochannel layer are etched
so that the bottom of the outlet microchannels end in the
device silicon. The resist is stripped after this stage. FIG. 16
25 presents a cross-section of a device at this stage of process-
ing.
An appropriate protection layer is applied to the surface
Ti/TiN (250/300A), Tungsten (5000 A) followed by Phos-
pho silicate Glass (PSG) of thickness of 1 um, which can be
30 used as both an HE protectant as well as a surface protectant.
The wafer is then turned upside down and a thick resist (10
um) is spun on. Using the front side alignment marks,
macrochannels are exposed on the backside. The macro-
channels are etched all the way through the wafer (about 700
35 um) using a Bosch DRIE process. This process lands on the
buried oxide, which forms an effective etch stop. FIG. 17
presents a cross-section of a test device at this stage of
processing. This buried oxide is then removed by a plasma
etch.
40 A series of wet etches are done to remove all the sacrificial
materials. A short buffered HE etch, for about 5 minutes, is
done to remove any residual oxide (of the buried oxide), as
well as to remove the PSG layer. The wafers are then
wet-etched in an SC-1 solution (hot Ammonium hydrox-
45 ide hydrogen peroxide mixture) for about 10 minutes to
remove the TiN barrier at the top surface as well as at the
bottom of the inlet microchannels. The wafers are subjected
to a piranha etch for about 20 minutes to remove the copper
in the inlet microchannels. This is followed by another SC-1
50 etch to remove all the TiN from the sidewalls of the inlet
microchannels. Finally, the Tungsten is removed from the
nanochannels by placing the wafers in wafer hydrogen
peroxide for 2 hours, followed by a rinse with DI water. The
wafers are then cleaned with Iso-Propyl Alcohol (IPA) to
55 displace the water with IPA, and the wafers are allowed to
dry.
Material Selection
Regardless of the protocol used to manufacture the nano-
channel delivery device, the materials used during the manu-
60 facturing process should be selected to successfully remove
sacrificial materials while leaving the non-sacrificial mate-
rials. As shown in FIG. 18, the selection of a nanochannel
"placeholder" (e.g., the sacrificial material used to fill the
space of the nanochannel) and nanochannel "ceiling" and
65 "floor" materials (e.g., the substrate and capping layers)
should be coordinated with the selection of a solvent or
etchant. Examples of suitable solvents and etchants that can
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be used to remove sacrificial materials while leaving the
substrate and capping layers are shown in FIG. 18. It is
understood that other combinations of materials may be
utilized as well.
Post Wafer Processing 5
During post wafer processing, each wafer is attached to a
tape-ring with an adhesive tape. A UV release tape is
preferred since it has better adhesion. Since both surfaces of
the wafer have critical device structures, UV tape is attached
to both top and bottom surfaces. The wafers are then diced 10
into individual die and cleaned. The tapeframe is then
exposed to a UV light source to decrease the adhesion of the
tape to the surface. The dice are individually picked and
placed into a bare-die holder using an automated pick and 15
place sorter tool. The tape on the top surface of the die is
subsequently peeled off manually. The dice are then indi-
vidually placed in a final clean container and cleaned with
acetone with a final rinse of IPA to promote channel drying.
A die is attached by epoxy or other fixing method to a 20
capsule mating surface.
Capsule Configurations
Referring now to FIGS. 19 and 20, nanochannel delivery
device 500 may form part of a larger assembly, e.g., a
capsule 600 that may be used to administer drugs or other 25
therapeutic agents to a patient. FIG. 19 shows a detailed
view of one end of capsule 600 in an exploded view, while
FIG. 20 illustrates an assembled view of capsule 600. It is
understood that in other embodiments, nanochannel delivery
device 500 may be used in other applications where it is 30
desired to precisely control the diffusion or passage of small
amounts of any substance.
In the embodiment shown in FIGS. 19 and 20, capsule
600 comprises a generally cylindrical body 620 having an
end portion 630 configured to receive a first cap 610 and a 35
second cap 625. In this embodiment, nanochannel delivery
device 500 is installed in a plane that is perpendicular to the
primary axis of capsule 600 (e.g., an axis that is parallel to
the length of cylindrical body 620 and concentric with
cylindrical body 620). End portion 630 also comprises a 40
recessed portion 640 configured to receive nanochannel
delivery device 500. In certain embodiments, a glue or other
boding agent may be used to secure nanochannel delivery
device 500 in recessed portion 640. When assembled, nano-
channel delivery device 500 can be inserted into recessed 45
portion 640, and first cap 610 may be fitted onto end portion
630.
During use, drugs (or any other substance administered
via capsule 600) can pass from cylindrical body 620 to
nanochannel delivery device via an inner volume 650 con- 50
tained within cylindrical body 620. After diffusing through
nanochannel delivery device 500 and into first cap 610, the
administered substances can exit cap 610 via exit ports 615.
In exemplary embodiments, the dimensions of exit ports 615
(and other aspects of capsule 610, such as inner volume 650 55
and cap 610) are large enough so that these features do not
restrict the diffusion of the administered substance from
capsule 600. As a result, the diffusion of the administered
substance can be more precisely controlled by selecting the
dimensions of nanochannel delivery device 500, particularly 60
the dimensions of nanochannels 505. Cap 610 may also
provide dimensional rigidity and protect nanochannel deliv-
ery device 500 from mechanical damage and the incursion
of biological tissue structures after implantation.
In certain embodiments, inner volume 650 is configured 65
to minimize capture points for air bubbles. For example,
inner volume 650 may comprise radiused corners and sur-
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faces that are not angled in a manner (when capsule 600 is
installed) which could trap air bubbles.
Referring now to FIGS. 21 and 22, capsule 700 is similar
to the previously-described capsule 600. However, in this
embodiment capsule 700 is fitted with a septum 760 on the
end of cylindrical body 720 that is distal from end portion
630. Septum 760 comprises a self-sealing material (e.g.,
silicone rubber) that permits injection of a therapeutic agent
into inner volume 750 of cylindrical body 720. In certain
embodiments, a therapeutic agent can be injected with a
hypodermic needle just prior to implantation of capsule 700.
Referring now to FIG. 23, a capsule 800 comprises
components equivalent to previously-described embodi-
ments. However, this embodiment comprises a cap 825 that
covers septum 860. Cap 825 may comprise an orifice (not
visible in the perspective view of FIG. 21) configured to
guide a needle or other device used to penetrate septum 860
and inject a therapeutic agent into inner volume 850 of
cylindrical body 820.
Referring now to FIG. 24, a capsule 900 comprises a
cylindrical body 922 coupled to a separate end component
935 and a cap 925. In this embodiment, cylindrical body 922
can be replaced with another cylindrical body having a
different length in order to vary the internal volume of
capsule 900 (and the amount of therapeutic agent that
capsule 900 can contain). Similar to previous embodiments,
end component 935 comprises an end portion 930 config-
ured to receive cap 910. End component 935 also comprises
a recessed portion 940 configured to receive nanochannel
delivery device 500.
Referring now to FIGS. 25 and 26, a capsule 1000
comprises a disc-shaped body 1020 with a cap 1010 com-
prising a series of exit ports 1015. In this embodiment,
disc-shaped body 1020 comprises a septum 1060 through
which a therapeutic agent may be injected. As shown in the
exploded view of FIG. 26, supports 1050 can be used to hold
nanochannel delivery device 500 proximal to exit ports
1015. In this manner, a therapeutic agent contained within
capsule 1000 is forced to pass through nanochannel delivery
device 500 proximal before exiting capsule 1000.
In the embodiment shown in FIGS. 27 and 28, a capsule
1100 comprises a rectangular planar surface 1121 and an
arched surface 1120. Capsule 1100 also comprises a closed
end 1125 and a septum 1160 that can be inserted into an open
end 1161. In the embodiment shown, septum 1160 covers
the entire open end 1161. In other embodiments, a septum
may cover part of an open end, and a cap may cover the
remaining portions. Similar to previously-described
embodiments, septum 1160 is self-sealing and can be punc-
tured with a needle to insert a therapeutic agent. Capsule
1100 also comprises a first recessed portion 1140 configured
to receive nanochannel delivery device 500, and a second
recessed portion 1130 configured to receive a cap 1110
comprising exit ports 1115. An aperture 1135 extends
through recessed portion 1140 into an inner volume 1150
bounded by rectangular planar surface 1121, arched surface
1120, closed end 1125 and septum 1160. In this embodiment,
a therapeutic agent can be contained within inner volume
1150 and dispensed through aperture 1135, nanochannel
delivery device 500, and exit ports 1115.
Referring now to FIG. 29, another embodiment of a
capsule 1200 is generally equivalent to capsule 1100, but
comprises features that accommodate two nanochannel
delivery devices (not shown). In this embodiment, capsule
1200 comprises a rectangular planar surface 1221, arched
surface 1220, closed end 1225 and septum 1260. Capsule
1200 also comprises a pair of first recessed portion 1240
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each configured to receive nanochannel delivery device (not
shown), and a second pair of recessed portions 1230 each
configured to receive a cap with exit ports (not shown). Each
recessed portion 1240 comprises an aperture 1235 that
provides fluid communication between inner volume 1250
and the environment surrounding capsule 1200.
In certain embodiments, inner volume 1250 comprises
separate, internal reservoirs in which each reservoir is in
fluid communication with a single aperture 1235. The inter-
nal reservoirs may be separated by inner walls within
aperture 1235. In such embodiments, each reservoir may be
filled with a separate therapeutic agent. Each nanochannel
device can be configured to provide the preferred dosage of
each individual therapeutic agent.
Referring now to FIG. 30, another embodiment of a
capsule 1300 is shown in an installed position so that it
partially extends beneath an epidermal surface 1301 of a
patient into which capsule 1300 has been inserted. Capsule
1300 comprises multiple covers 1310 with exit ports 1315.
Beneath each cover 1310, a nanochannel delivery device is
inserted over an aperture that is in fluid communication with
an inner volume of capsule 1300 (similar to the embodi-
ments described in FIGS. 27-29). The inner volume of
capsule 1300 may be divided into separate compartments so
that each nanochannel delivery device can be used to
administer a specific and distinct therapeutic agent. Capsule
1300 also comprises an anchor member 1305 configured to
serve as a point at which a suture (not shown) can be
attached to capsule 1300 when it is installed. Anchor mem-
ber 1305 may also be coupled to a string or other device (not
shown) used to remove or retrieve capsule 1300.
Referring now to FIG. 31, another embodiment of a
capsule 1400 is shown. This capsule is a minimal covering
of the back and sides of the nanochannel device, such that
the "reservoir" for a contained drug is limited to the volume
of the macrochannels on the back of the chip (e.g., the
nanochannel delivery device), which is about 4.5 mm3 for
the embodiment shown in FIG. 8K. This embodiment can be
made particularly small, for example 2 mmx2 mmx0.5 mm,
and is, therefore, especially suited for implantation with very
high potency drugs into sensitive locations, e.g., glaucoma
medication into the inner portion of the eye.
Exemplary embodiments of the previously-described cap-
sules can be sized so that the capsule may be implanted
subcutaneously. In specific embodiments, the capsule may
have a diameter of 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3,
1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7,
2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4. 1,
4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 6.0, 7.0, 8.0, 9.0,
10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0 or
20.0 mm. In other embodiments, the capsule may be greater
than 20.0 mm in diameter.
In certain embodiments, the capsule may have a thickness
of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3,
1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7,
2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4. 1,
4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5,
5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9,
7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3,
8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7,
9.8, 9.9 or 10.0 mm. In other embodiments, the capsule may
have a thickness greater than 10.0 mm.
In specific embodiments, a capsule may have a width of
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,
36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51,
52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67,
w1i
68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83,
84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,
100 mm. In other embodiments, the capsule may have a
width greater than 100 mm.
5 In specific embodiments, a capsule may have a length of
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,
36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51,
52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67,
io 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83,
84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,
100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111,
112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123,
124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135,
15 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147,
148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159,
160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171,
172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183,
184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195,
20 196, 197, 198, 199 or 200 mm. In other embodiments, the
capsule may have a length greater than 200 mm.
It is noted that the various embodiments of capsules
described in this disclosure comprise a cross-section that is
nominally constant along the length of the capsule. Such an
25 optional configuration can facilitate sliding removal from a
surgical site within the body without damage to surrounding
tissue.
In exemplary embodiments a capsule may comprise suit-
able materials such as stainless steel, titanium, polyethere-
30 therkeytone, polysulfone, and other plastics and metals. In
certain embodiments, a capsule may comprise coating(s) on
the interior to provide an optimal environment for a thera-
peutic substance and/or coating(s) on the exterior to prevent
deleterious tissue encapsulation. In specific embodiments,
35 the capsule may comprise color coding to indicate the model
of the capsule or a particular characteristic (e.g., the thera-
peutic agent, rate of administering the agent, the capacity of
the capsule, etc.). In certain embodiments, a capsule may
comprise a translucent or transparent portion or component
40 (e.g. a cap) to facilitate observation of the quantity of
therapeutic agent contained within the capsule. For example,
a translucent or transparent cap covering the nanochannel
delivery device can allow a person to confirm the capsule is
full by orienting the capsule so that the nanochannel delivery
45 device is positioned towards the top of the capsule. A needle
(or other loading device) can then penetrate the septum and
the therapeutic agent can be injected into the capsule. When
liquid appears on the top of the nanochannel delivery device
(as viewed through the cap), the person filling the capsule
50 will have an indication that the capsule is full.
In exemplary embodiments, a capsule may be used to
administer one or more of the following substances: adren-
ergic agent; adrenocortical steroid; adrenocortical suppres-
sant aldosterone; alkylating agent; antagonist; amino acid;
55 anabolic; analeptic; analgesic; anesthetic; anorexogenic;
anti-acne agent; anti-adrenergic; anti-allergic; anti-alopecia
agent; anti-amebic; anti-anemic; anti-anginal; antiangio-
genic, anti-anxiety; anti-arthritic; anti-asthmatic; anti-ath-
erosclerotic; antibacterial; antibiotic; anticancer; anticholin-
60 ergic; anticoagulant anticonvulsant; antidepressant;
antidiabetic; antidiarrheal; antidiuretic; anti-dyskinetic; anti-
emetic; anti-epileptic; antifibrinolytic; antifungal; anti-hem-
orrhagic; antihistamine; anti-hypercalcemic, anti-hypercho-
lesterolaemic; anti-hyperlipidaemic; anti-hypertensive; anti-
65 hypertriglyceridemic; anti-hypotensive; anti-infective; anti-
inflammatory; anti-ischemic; antimicrobial; antimigraine;
antimitotic; antimycotic; anti-nauseant; anti-neoplastic;
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anti-neutropenic; anti-obesity agent; anti-osteoporotic, anti-
parasitic; antiproliferative; antipsychotic; antiretroviral;
anti-resorptives; anti-rheumatic; anti-seborrheic; antisecre-
tory; antispasmodic; antisclerotic; antithrombotic; antitu-
mor; anti-ulcerative; antiviral; appetite suppressant; bispho- 5
sphonate; blood glucose regulator; bronchodilator;
cardiovascular agent; central nervous system agent; contra-
ceptive; cholinergic; concentration aid; depressant; diagnos-
tic aid; diuretic; DNA-containing agent, dopaminergic
agent; estrogen receptor agonise fertility agent; fibrinolytic; io
fluorescent agent; free oxygen radical scavenger; gastric
acid supressant; gastrointestinal motility effector; glucocor-
ticoid; glutamatergic agent; hair growth stimulant; hemo-
static; histamine H2 receptor antagonist; hormone; hypoc-
holesterolemic; hypoglycemic; hypolipidemic; hypotensive; 15
imaging agent; immunizing agent; immunomodulator;
immunostimulane immunosuppressant; interleukin, kera-
tolytic; LHRH agonist; mood regulator; mucolytic; mydri-
atic; nasal decongestant; neuromuscular blocking agent;
neuroprotective; NMDA antagonist; non-hormonal sterol 20
derivative; nootropic agent; parasympathomimetic agent;
plasminogen activator; platelet activating factor antagonist;
platelet aggregation inhibitor; platinum-containing agent,
psychotropic; radioactive agent; raf antagonist, RNA-con-
taining agent, scabicide; sclerosing agent; sedative; seda- 25
tive-hypnotic; selective adenosine Al antagonist; selective
estrogen receptor modulator, serotonin antagonist; serotonin
inhibitor; serotonin receptor antagonist; steroid; stimulant;
thrombic agent; thyroid hormone; thyroid inhibitor; thyro-
mimetic; tranquilizer; vasoconstrictor; vasodilator; wound 30
healing agent; xanthine oxidase inhibitor; and the like;
Abacavir, Abacavir sulfate, abatacepe Acarbose, Acet-
aminophen, Aciclovir, Adalimumab, Adapalene, Alendro-
nate, Alendronate sodium, Alfuzosin, aliskiren, allopurinol,
alvimopan, ambrisentan, Aminocaproic acid, Amitriptyline 35
hydrochloride, amlodipine, amlodipine besylate, amoxicil-
lin, amoxicilline, Amphetamine, Anastrozole, Aripiprazole,
annodafinil, Atazanavir, atenolol, Atomoxetine, atorvastatin
calcium, atorvastatin, Atropine sulfate, Azelastine, azithro-
mycin, Balsalazide, Benazepril, bendamustine hydrochlo- 40
ride, Benzepril hydrochloride, bevacizumab, Bicalutamide,
Bimatoprost, Bisoprolol, Bisoprolol fumarate, Bosentan,
Botulin toxin, Budesonide, Buformin, Buprenorphine,
Bupropion, bupropion hydrobromide, Bupropion Hydro-
chloride, Cabergoline, Calcipotriol, calcitriol, candesartan 45
cilexetil, Capecitabine, Captopril, carbidopa, carisoprodol,
Carvedilol, Caspofungin, Cefdinir, Cefoperazone, Cefotiam,
cefprozil, Cefuroxime, Celecoxib, cephalaxin, Certolizumab
Pegol, Cetirizine, Cetrizine hydrochloride, Cetuximab,
Chlorpromazine hydrochloride, Chlorpheniramine maleate, 50
ciclesonide, Cilastatin, cimetidine, Cinacalcee Ciprofloxa-
cin, citalopram hydrobromide, Clarithromycin, Clindamy-
cin, Clindamycin, clindamycin hydrochloride, Clomip-
ramine hydrochloride, Clonidine hydrochloride,
clopidogrel, Clopidogrel bisulfate, Cloxacillin Sodium, Co- 55
Amoxiclav, Codeine phosphate, Colchicines, Colesevelam,
cyclobenzaprine hydrochloride, Cyclophosphamide,
Cyclosporine, darbepoetin alfa, Darifenacin, DCRM 197
protein, Desloratadine, desloratidine, Desmopressin sulfate,
Desoximetasone, dexamethasone, Diclofenac, Diethylcar- 60
bamazine citrate, difluprednate, diphenhydramine,
Dipyridamole, DL-methionine, Docetaxel, Donepezil,
doripenem, Dorzolamide, Doxazosin, doxazosin mesylate,
doxycydine, Drospirenone, Duloxetine, Dutasteride, eculi-
zumab, Efavirenz, Emtricitabine, Enalapril, enalapril 65
maleate, Enoxaparin Sodium, Eprosartan, Erlotinib, Eryth-
romycin, Erythropoetin, Escitalopram, esomeprazole, estra-
28
diol, Estrogen, Eszopiclone, etanercept, Ethembutol hydro-
chloride, Ethosuximide, ethynl estradiol, etonogestrel,
etoricoxib, etravirine, Exenatide, Ezetimibe, Ezetimibe,
Factor VII, famotidine, Famotidine, Fenofibrate, Fenofi-
brate, Fentanyl, Fentanyl citrate, Ferrous sulfate, Fexofena-
dine, fexofenadine hydrochloride, Filgrastim, Finasteride,
fluconazole, Fluoxetine hydrochloride, Fluticasone, Fluvas-
tatin, folic acid, Follitropin alfa, Follitropin beta, For-
moterol, Fosinopril sodium, Gabapentin, Gabapentin, Gem-
citabine, glargine insulin, Glatiramer, glimepride, Goserelin,
histrelin acetate, Human growth hormone, Hydralazine
hydrochloride, Hydrocodone bitartrate, Hydroxyurea,
Hydroxyzine hydrochloride, Ibandronate, Imatinib, Imiglu-
cerase, Imipenem, imiquimod, Indinavir sulfate, infliximab,
Interferon beta-la, Ipratropium, Irbesartan, Irinotecan, Iso-
niazid, Isosorbide moninitrate, ixabepilone, ketamine, keto-
conazole, Ketorolac, Lactobionate, Lamivudine, Lamivu-
dine, Lamotrigine, lanreotide acetate, Lansoprazole,
lapatinib, laropiprane Latanoprose Letrozole, Leuprolide,
Levalbuterol, Levamisole hydrochloride, Levetiracetam,
levocetirizine dihydrochloride, levodopa, Levofloxacin,
levonorgestrel, Levothyroxine, levothyroxine sodium, Lido-
caine, Linezolid, Lisdexamfetamine Dimesylate, Lisinopril,
Lispro insulin, Lopinavir, Loratadine, lorazepam, Losartan
potassium, maraviroc, Marinol, meclizine hydrochloride,
Meloxicam, Memantine, Meropenem, metaxalone, met-
formin, Metformin Hydrochloride, methadone, methoxy
polyethylene glycol-epoetin beta, Methylphenidate, Meth-
ylphenidate hydrochloride, Metoprolol, Metoprolol tartrate,
metronidazole, Metronidazole, miglitol, Minocycline,
Minocycline hydrochloride, mirtazepine, Modafinil,
Mometasone, montelukast, Montelukast sodium, Morphine,
Moxifloxacin, Mycophenolate mofetil, Naloxone, Naproxen
sodium, natalizumab, Neostigmine bromide, Niacin, Nico-
tinamide, Nifedipine, Nifurtimox, nilotinib hydrochloride
monohydrate, nitrofurantoin, Nortriptyline hydrochloride,
nystatin, olanzapine, Olanzepine, Olmesartan, olmesartan
medoxomil, olopatadine hydrochloride, Omalizumab,
Omega-3 acid ethyl esters, Omeprazole, Ondansetron, Orl-
istae Oseltamivir, Oxaliplatin, Oxcarbazepine, Oxybytynin
chloride, oxycodone hydrochloride, Paclitaxel, Palivi-
zumab, Pantoprazole, paracetamol, Paroxetine, paroxetine
hydrochloride, Pegylated interferon alfa-2a, Pemetrexed,
Penicillamine, Penicillin V potassium, Phenformin, Pheny-
loin sodium, Pioglitazone, Piperacillin, Potassium chloride,
Pramipexole, Pravastatin, Pravastatin sodium, prednisolone
quetiapine fumerate, Pregabalin, Primaquine phosphate,
Progesterone, Promethazine, Promethazine hydrochloride,
Proponolol hydrochloride, Propoxyphene hydrochloride,
pseudoephedrine, Pseudophedrine hydrochloride, Pyri-
dostigmine bromide, Pyridoxine hydrochloride, Quetiapine,
quetiapine fumarate, Quinapril hydrochloride, Rabeprazole,
raloxifene, raltegravir, Ramipril, Ranitidine, Ranitidine
hydrochloride, Recombinant factor VIII, retapamulin,
Rimonabane Risedronate, Risedronate sodium, risperidone,
Ritonavir, rituximab, Rivastigmine, rivastigmine tartrate,
Rizatriptan, Ropinirole, rosiglitazone, Rosiglitazone
maleate, Rosuvastatin, Rotavirus vaccine, rotigotine, Salbu-
tamol, Salbutamol sulfate, salmeterol, sapropterin dihydro-
chloride, Sertraline, sertraline hydrochloride, Sevelamer,
Sevoflurane, Sildenafil, sildenafil citrate, simvastatin, Sim-
vastatin, Sitagliptin, Sodium valproate, Solifenacin, Soma-
tostatin, Somatropin, Stavudine, Sulfomethoxazole,
Sumatriptan, Sumatriptan succinate, Tacrolimus, Tadalafil,
tamoxifen citrate, Tamsulosin, tamsulosin hydrochloride,
Tegaserod, Telmisartan, temazepam, Temozolomide, temsi-
rolimus, Tenofovir, Terazosin Hydrochloride, Terbinafine,
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Teriparatide, testosterone, Tetracycline hydrochloride, Tha-
lidomide, thymopentin, Timolol meleate, Tiotropium, tipra-
navir, Tolterodine, tolterodine tartrate, topiramate, topote-
can, Tramadol, Tramodol hydrochloride, trastuzumab,
trazodone hydrochloride, trimethoprim, Valaciclovir, Vala-
cyclovir hydrochloride, Valproate semisodium, valsartan,
Vancomycin, Vardenafil, Varenicline, venlafaxine, Venlafax-
ine hydrochloride, Verapamil Hydrochloride, vildagliptin,
Voglibose, Voriconazole, Wafarin sodium acetylsalicylic
acid, Zaleplon, Zidovudine, Ziprasidone, Zoledronate,
Zolpidem, or pharmaceutically acceptable salts thereof;
16-alpha fluoroestradiol, 17-alpha dihydroequilenin, 17-al-
pha estradiol, 17-beta estradiol, 17-hydroxyprogesterone,
1-dodecpyrrolidinone, 22-oxacalcitriol, 3-isobutyl-gamma-
butyric acid, 6-fluoroursodeoxycholic acid, 7-methoxyta-
crine, Abacavir, Abacavir sulfate, Abamectin, abanoquil,
abatacept, abecarnil, abiraterone, Ablukast, Ablukast
Sodium, Acadesine, acamprosate, Acarbose, Acebutolol,
Acecamide Hydrochloride, Aceclidine, aceclofenae,
Acedapsone, Acedapsone, Aceglutamide Aluminum, Ace-
mannan, Acetaminophen, Acetazolamide, Acetohexamide,
Acetohydroxamic Acid, acetomepregenol, Acetophenazine
Maleate, Acetosulfone Sodium, Acetylcholine Chloride,
Acetylcysteine, acetyl-L-carnitine, acetylmethadol, Aciclo-
vir, Acifran, acipimox, acitemate, Acitretin, Acivicin, Acla-
rubicin, aclatonium, Acodazole Hydrochloride, aconiazide,
Acrisorcin, Acrivastine, Acronine, Actisomide, Actodigin,
Acyclovir, acylfulvene, Adatanserin Hydrochloride,
adafenoxate, Adalimumab, Adapalene, adatanserin, adecy-
penol, adecypenol, Adefovir, adelmidrol, ademetionine,
Adenosine, Adinazolam, Adipheinine Hydrochloride, adi-
posin, Adozelesin, adrafinil, Adrenalone, Aiclometasone
Dipropionate, airbutamine, alacepril, Alamecin, Alanine,
Alaproclate, alaptide, Albendazole, albolabrin, Albuterol,
Alclofenae, Alcloxa, aldecalmycin, Aldesleukin, Aldioxa,
Aletamine Hydrochloride, Alendronate, Alendronate
Sodium, alendronic acid, alentemol, Alentemol Hydrobro-
mide, Aleuronium Chloride, Alexidine, alfacalcidol, Alfen-
tanil Hydrochloride, alfuzosin, Algestone Acetomde, alglu-
cerase, Aliflurane, alinastine, Alipamide, aliskiren,
Allantoin, Allobarbital, Allopurinol, Alonimid, alosetron,
Alosetron Hydrochloride, Alovudine, Alpertine, alpha-
idosone, Alpidem, Alprazolam, Alprenolol Hydrochloride,
Alprenoxime Hydrochloride, Alprostadil, Alrestatin
Sodium, Altanserin Tartrate, Alteplase, Althiazide, Altret-
amine, altromycin B, Alverinc Citrate, alvimopan, Alvircept
Sudotox, Amadinone Acetate, Amantadine Hydrochloride,
ambamustine, Ambomycin, ambrisentan, Ambruticin,
Ambuphylline, Ambuside, Amcinafal, Amcinonide, Amdi-
nocillin, Amdinocillin Pivoxil, Amedalin Hydrochloride,
amelometasone, Ameltolide, Amesergide, Ametantrone
Acetate, amezinium metilsulfate, amfebutamone, Amfenac
Sodium, Amfiutizole, Amicycline, Amidephrine Mesylate,
amidox, Amifloxacin, amifostine, Amilcacin, Amiloride
Hydrochloride, Aminacrine Hydrochloride, Aminobenzoate
Potassium, Aminobenzoate Sodium, Aminocaproic Acid,
Aminoglutethimide, Aminohippurate Sodium, aminolevu-
linic acid, Aminophylline, A minorex, Aminosalicylate
sodium, Aminosalicylic acid, Amiodarone, Amiprilose
Hydrochloride, Amiquinsin Hydrochloride, amisulpride,
Amitraz, Amitriptyline Hydrochloride, Amlexanox, amlo-
dipine, amlodipine besylate, Amobarbital Sodium, Amodia-
quine, Amodiaquine Hydrochloride, Amorolfine, Amoxap-
ine, Amoxicillin, Amphecloral, Amphetamine,
Amphetamine Sulfate, Amphomycin, Amphoterin B, Ampi-
cillin, ampiroxieam, Ampyzine Sulfate, Amquinate, Amri-
none, amrubicin, Amsacrine, Amylase, amylin, amythiami-
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cin, Anagestone Acetate, anagrelide, Anakinra, ananain,
anaritide, Anaritide Acetate, Anastrozole, Anazolene
Sodium, Ancrod, andrographolide, Androstenedione, Angio-
tensin Amide, Anidoxime, Anileridine, Anilopam Hydro-
5 chloride, Aniracetam, Anirolac, Anisotropine Methylbro-
mide, Anistreplase, Anitrazafen, anordrin, antagonist D,
antagonist G, antarelix, Antazoline Phosphate, Anthelmycin,
Anthralin, Anthramy ci antiandrogen, antiestrogen, antine-
oplaston, Antipyrine, antisense oligonucleotides, apadoline,
io apafant, Apalcillin Sodium, apaxifylline, Apazone, aphidi-
colin glycinate, Apixifylline, Apomorphine Hydrochloride,
apraclonidine, Apraclonidine Hydrochloride, Apramycin,
Aprindine, Aprindine Hydrochloride, aprosulate sodium,
Aprotinin, Aptazapine Maleate, aptiganel, apurinic acid,
15 apurinic acid, aranidipine, Aranotin, Arbaprostil, arbekicin,
arbidol, Arbutamine Hydrochloride, Arclofenin, Ardeparin
Sodium, argatroban, Arginine, Argipressin Tannate, Aril-
done, Aripiprazole, armodafinil, arotinolol, Arpinocid, Arte-
flene, Artilide Fumarate, asimadoline, aspalatone, Aspara-
20 ginase, Aspartic Acid, Aspartocin, asperfuran, Aspirin,
aspoxicillin, Asprelin, Astemizole, Astromicin Sulfate, asu-
lacrine, atamestane, Atazanavir, Atenolol, atevirdine, Atipa-
mezole, Atiprosin Maleate, Atolide, Atomoxetine, atorvas-
tatin, Atorvastatin Calcium, Atosiban, Atovaquone, atpenin
25 B, Atracurium Besylate, atrimustine, atrinositol, Atropine,
Atropine sulfate, Auranofin, aureobasidin A, Aurothioglu-
cose, Avilamycin, Avoparcin, Avridine, Axid, axinastatin 1,
axinastatin 2, axinastatin 3, Azabon, Azacitidinie, Azaclor-
zine Hydrochloride, Azaconazole, azadirachtine, Azalanstat
3o Dihydrochloride, Azaloxan Fumarate, Azanator Maleate,
Azanidazole, Azaperone, Azaribine, Azaserine, azasetron,
Azatadine Maleate, Azathioprine, Azathioprine Sodium,
azatoxin, azatyrosine, azelaic acid, Azelastine, azelnidipine,
Azepindole, Azetepa, azimilide, Azithromycin, Azlocillin,
35 Azolimine, Azosemide, Azotomycin, Aztreonam, Azu-
molene Sodium, Bacampicillin Hydrochloride, baccatin III,
Bacitracin, Baclofen, bacoside A, bacoside B, bactobo-
lamine, balanol, balazipone, balhimycin, balofloxacin, bal-
salazide, Bambermycins, bambuterol, Bamethan Sulfate,
4o Bamifylline Hydrochloride, Bamidazole, baohuoside 1, Bar-
mastine, bamidipine, Basic, Basifungin, Batanopride
Hydrochloride, batebulast, Batelapine Maleate, Batimastat,
beau vericin, Becanthone Hydrochloride, becaplermin,
becliconazole, Beclomethasone Dipropionate, befloxatone,
45 Beinserazide, Belfosdil, Belladonna, Beloxamide, Bemese-
tron, Bemitradine, Bemoradan, Benapryzine Hydrochloride,
Benazepril, Benazepril Hydrochloride, Benazeprilat, Benda
calol Mesylate, bendamustine hydrochloride, Bendazac,
Bendroflumethiazide, benflumetol, benidipine, Benorterone,
5o Benoxaprofen, Benoxaprofen, Benoxinate Hydrochloride,
Benperidol, Bentazepam, Bentiromide, Benurestat, Benz-
bromarone, Benzepril hydrochloride, Benzethonium Chlo-
ride, Benzetimide Hydrochloride, Benzilonium Bromide,
Benzindopyrine Hydrochloride, benzisoxazole, Benzocaine,
55 benzochlorins, Benzoctamine Hydrochloride, Benzodepa,
benzoidazoxan, Benzonatate, Benzoyl Peroxide, benzoyl-
staurosporine, Benzquinamide, Benzthiazide, benztropine,
Benztropine Mesylate, Benzydamine Hydrochloride, Ben-
zylpenicilloyl Polylysine, bepridil, Bepridil Hydrochloride,
60 Beractant, Beraprost, Berefrine, berlafenone, bertosamil,
Berythromycin, besipirdine, betaalethine, betaclamycin B,
Betamethasone, betamipron, betaxolol, Betaxolol Hydro-
chloride, Bethanechol Chloride, Bethanidine Sulfate, betu-
linic acid, bevacizumab, bevantolol, Bevantolol Hydrochlo-
65 ride, Bezafibrate, Bialamicol Hydrochloride, Biapenem,
Bicalutamide, Bicifadine Hydrochloride, Biclodil Hydro-
chloride, Bidisomide, bifemelane, Bifonazole, bimakalim,
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Bimatoprost, bimithil, Bindarit, Biniramycin, binospirone,
bioxalomycin, Bipenamol Hydrochloride, Biperiden, Biphe-
namine Hydrochloride, biriperone, bisantrene, bisaramil,
bisaziridinylspermine, bis-benzimid zole A, bis-benzimida-
zole B, bisnafide, Bisobrin Lactate, Bisoprolol, Bisoprolol
fumarate, Bispyrithione Magsulfex, bistramide D, bistr-
amide K, bistratene A, Bithionolate Sodium, Bitolterol
Mesylate, Bivalirudin, Bizelesin, Bleomycin Sulfate, bold-
ine, Bolandiol Dipropionate, Bolasterone, Boldenone Unde-
cylenate, Bolenol, Bolmantalate, bopindolol, Bosentan,
Botulin toxin, Boxidine, brefeldin, breflate, Brequinar
Sodium, Bretazenil, Bretylium Tosylate, Brifentanil Hydro-
chloride, brimonidine, Brinolase, Brocresine, Brocrinat,
Brofoxine, Bromadoline Maleate, Bromazepam, Bromchlo-
renone, Bromelain, bromfenac, Brominidione, Bromocrip-
tine, Bromodiphenhydramine Hydrochloride, Bromoxanide,
Bromperidol, Bromperidol Decanoate, Brompheniramine
Maleate, Broperamole, Bropirimine, Brotizolam, Bucamide
Maleate, bucindolol, Buclizine Hydrochloride, Bucromar
one, Budesonide, budipine, budotitane, Buformin,
Bumetanide, Bunaprolast, bunazosin, Bunolol Hydrochlo-
ride, Bupicomide, Bupivacaine Hydrochloride, Buprenor-
phine, Buprenorphine Hydrochloride, Bupropion, bupropion
hydrobromide, Bupropion Hydrochloride, Buramate, Buser-
elin Acetate, Buspirone Hydrochloride, Busulfan, Butabar-
bital, Butacetin, Butaclamol Hydrochloride, Butalbital,
Butamben, Butamirate Citrate, Butaperazine, Butaprost,
Butedronate Tetrasodium, butenafine, Buterizine, buthion-
inc sulfoximine, Butikacin, Butilfenin, Butirosin Sulfate,
Butimrate, butixocort propionate, Butoconazole Nitrate,
Butonate, Butopamine, Butoprozine Hydrochloride, Butor-
phanol, Butoxamine Hydrochloride, Butriptyline Hydro-
chloride, Cabergoline, Cactinomycin, Cadexomer Iodine,
Caffeine, calanolide A, Calcifediol, Calcipotriene, calcipot-
riol, Calcitonin, Calcitriol, Calcium Undecylenate, cal-
phostin C, Calusterone, Cambendazole, Cammonam
Sodium, camonagrel, canary pox IL-2, candesartan, cande-
sartan cilexetil, Candicidin, candoxatril, candoxatrilat, Can-
iglibose, Camenoate Potassium, Canrenone, capecitabine,
Capobenate Sodium, Capobenic Acid, Capreomycin Sulfate,
capromab, capsaicin, Captopril, Capuride, Car bocysteine,
Caracemide, Carbachol, Carbadox, Carbamazepine, Carb-
amide Peroxide, Carbantel Lauryl Sulfate, Carbaspirin Cal-
cium, Carbazeran, carbazomycin C, Carbenicillin Potas-
sium, Carbenoxolone Sodium, Carbetimer, carbetocin,
Carbidopa, Carbidopa-Levodopa, Carbinoxamine Maleate,
Carbiphene Hydrochloride, Carbocloral, Carbol-Fuchsin,
Carboplatin, Carboprost, carbovir, carboxamide-amino-tri-
azo-le, carboxyamidotriazole, carboxymethylated beta-1,3-
glucan, Carbuterol Hydrochloride, CaRest M3, Carfentanil
Citrate, Carisoprodol, Carmantadine, Carmustine, CARN
700, Camidazole, Caroxazone, carperitide, Carphenazine
Maleate, Carprofen, Carsatrin Succinate, Cartazolate, car-
teolol, Carteolol Hydrochloride, Carubicin Hydrochloride,
carvedilol, carvotroline, Carvotroline Hydrochloride, carze-
lesin, Caspofungin, castanospernine, caurumonam, cebar-
acetam, cecropin B, Cedefingol, Cefaclor, Cefadroxil, Cefa-
mandole, Cefaparole, Cefatrizine, Cefazaflur Sodium,
Cefazolin, cefcapene pivoxil, cefdaloxime pentexil tosilate,
Cefdinir, cefditoren pivoxil, Cefepime, cefetamet, Cefete-
col, cefixime, cefluprenam, Cefinenoxime Hydrochloride,
Cefinetazole, cefminlox, cefodizime, Cefonicid Sodium,
Cefoperazone, Cefoperazone Sodium, Ceforanide, cefoselis,
Cefotaxime Sodium, Cefotetan, cefotiam, Cefoxitin, cefo-
zopran, cefpimizole, Cefpiramide, cefpirome, cefpodoxime
proxetil, cefprozil, Cefroxadine, cefsulodin, Ceftazidime,
cefteram, ceftibuten, Ceftizoxime Sodium, ceftriaxooe,
ON
Cefuroxime, celastrol, Celecoxib, celikalim, celiprolol,
cepacidiine A, Cephacetrile Sodium, Cephalexin, Cephalo-
glycin, Cephaloridine, Cephalothin Sodium, Cephapirin
Sodium, Cephradine, cericlamine, cerivastatin, Ceruletide,
5 Ceronapril, Certolizumab Pegol, certoparin sodium, Ceta-
ben Sodium, Cetalkonium Chloride, Cetamolol Hydrochlo-
ride, Cethuperazone, cetiedil, cetirizine, Cetophenicol,
Cetraxate Hydrochloride, Cetrizine hydrochloride, cetrore-
lix, Cetuximab, Cetylpyridinium Chloride, Chenodiol,
io Chlophedianol Hydrochloride, Chloral Betaine, Chlorambu-
cil, Chloramphenicol, Chlordantoin, Chlordiazepoxide,
Chlorhexidine Gluconate, chlorins, Chlormadinone Acetate,
chloroorienticin A, Chloroprocaine Hydrochloride, Chloro-
propamide, Chloroquine, chloroquinoxaline sulfonamide,
15 Chlorothiazide, Chlorotrianisene, Chloroxine, Chloroxyle-
nol, Chlorphe niramine Maleate, Chlorphenesin Carbamate,
Chlorpheniramine maleate, Chlorpromazine, Chlorpromaz-
ine hydrochloride, Chlorpropamide, Chlorprothixene, Chlo-
rtetracycline Bisulfate, Chlorthalidone, Chlorzoxazone,
20 Cholestyramine Resin, Chromonar Hydrochloride, cibenzo-
line, cicaprost, Ciclafrine Hydrochloride, Ciclazindol, cicle-
sonide, cicletanine, Ciclopirox, Cicloprofen, cicloprolol,
Cidofovir, Cidoxepin Hydrochloride, Cifenline, Ciglitazone,
Ciladopa Hydrochloride, cilansetron, Cilastatin, Cilastatin
25 Sodium, Cilazapril, cilnidipine, Cilobamine Mesylate, cilo-
bradine, Cilofungin, cilostazol, Cimaterol, Cimetidine,
cimetropium bromide, Cinacalcet, Cinalukast, Cinanserin
Hydrochloride, Cinepazet Maleate, Cinflumide, Cingestol,
cinitapride, Cinnamedrine, Cinnarizine, cinolazepam, Cino-
30 xacin, Cinperene, Cinflomide, Cintazone, Cintriamide, Ciot
eronel, Cipamfylline, Ciprefadol Succinate, Ciprocinonide,
Ciprofibrate, Ciprofloxacin, ciprostene, Ciramadol, Cirole-
mycin, C is platin, cisapride, cisatracurium besilate, Ciscon-
azole, cis-porphyrin, cistinexine, citalopram, citalopram
35 hydrobromide, Citenamide, citicoline, citreamicin alpha,
cladribine, Clamoxyquin Hydrochloride, Clarithromycin,
clausenamide, Clavulanate Potassium, Clazolam, Clazolim-
ine, clebopride, Clemastine, Clentiazem Maleate, Clidinium
Bromide, clinafloxacin, Clindamycin, clindamycin hydro-
40 chloride, Clioquinol, Clioxanide, Cliprofen, clobazam, Clo-
betasol Propionate, Clobetasone Butyrate, Clocortolone
Acetate, Clodanolene, Clodazon Hydrochloride, clodronic
acid, Clofazimine, Clofibrate, Clofilium Phosphate, Cloge
stone Acetate, Clomacran Phosphate, Clomegestone
45 Acetate, Clometherone, clomethiazole, clomifene ana-
logues, Clominorex, Clomiphene, Clomipramine Hydro-
chloride, Clonazepam, Clonidine, Clonidine hydrochloride,
Clofibrate, Clonixeril, Clonixin, Clopamide, Clopenthixol,
Cloperidone Hydrochloride, clopidogrel, Clopidogrel bisul-
50 fate, Clopimozide, Clopipazan Mesylate, Clopirac, Clopred-
nol, Cloprostenol Sodium, Clorazepate Dipotassium, Clore-
thate, Clorexolone, Cloroperone Hydrochloride,
Clorprenaline Hydrochloride, Clorsulon, Clortemine Hydro-
chloride, Closantel, Closiramine Aceturate, Clothiapine,
55 Clothixamide Maleate Cloticasone Propionate, Clotrima-
zole, Cloxacillin Benzathine, Cloxacillin Sodium, Cloxy-
quin, Clozapine, Co-Amoxiclav, Cocaine, Coccidioidin,
Codeine, Codeine phosphate, Codoxime, Colchicine, Cole-
sevelam, colestimide, Colestipol Hydrochloride, Coles-
60 tolone, Colforsin, Colfosceril Palmitate, Colistimethate
Sodium, Colistin Sulfate, collismycin A, collismycin B,
Colterol Mesylate, combretastatin A4, complestatin, con-
agenin, Conorphone Hydrochloride, contignasterol, contor-
trostatin, Cormethasone Acetate, Corticorelin Ovine Tnflu-
65 tate, Corticotropin, Cortisone Acetate, Cortivazol,
Cortodoxone, cosalane, costatolide, Cosyntropin, cotinine,
Coumadin, Coumermycin, crambescidin, Crilvastatin, cris-
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natol, Cromitrile Sodium, Cromolyn Sodium, Crotamiton,
cryptophycin, cucumariosid, Cuprimyxin, curacin A, curd-
Ian sulfate, curiosin, Cyclacillin, Cyclazocine, cyclazosin,
Cyclindole, Cycliramine Maleate, Cyclizine, Cyclobenda-
zole, cyclobenzaprine, cyclobenzaprine hydrochloride, 5
cyclobutA, cyclobut G, cyclocapron, Cycloguanil Pamoate,
Cycloheximide, cyclopentanthraquinones, Cyclopenthiaz-
ide, Cyclopentolate Hydrochloride, Cyclophenazine Hydro-
chloride, Cyclophosphamide, cycloplatam, Cyclopropane,
Cycloserine, cyclosin, Cyclosporine, cyclothialidine, io
Cyclothiazide, cyclothiazomycin, Cyheptamide, cypemycin,
Cyponamine Hydrochloride, Cyprazepam, Cyproheptadine
Hydrochloride, Cyprolidol Hydrochloride, cyproterone,
Cyproximide, Cysteamine, Cysteine Hydrochloride, Cys-
tine, Cytarabine, Cytarabine Hydrochloride, cytarabine 15
ocfosfate, cytochalasin B, cytostatin, Dacarbazine, daclix-
imab, dactimicin, Dactinomycin, daidzein, Daledalin Tosy-
late, dalfopristin, Dalteparin Sodium, Daltroban, Dalvasta-
tin, danaparoid, Danazol, Dantrolene, daphlnodorin A,
dapiprazole, dapitant, Dapoxetine Hydrochloride, Dapsone, 20
Daptomycin, darbepoetin alfa, Darglitazone Sodium,
darifenacin, darlucin A, Darodipine, darsidomine, Daunoru-
bicin Hydrochloride, Dazadrol Maleate, Dazepinil Hydro-
chloride, Dazmegrel, Dazopride Fumarate, Dazoxiben
Hydrochloride, DCRM 197 protein, Debrisoquin Sulfate, 25
Decitabine, deferiprone, deflazacort, Dehydrocholic Acid,
dehydrodidemnin B, Dehydroepiandrosterone, delapril, Del-
april Hydrochloride, Delavirdine Mesylate, delequamine,
delfaprazine, Delmadinone Acetate, delmopinol, delphini-
din, Demecarium Bromide, Demeclocycline, Demecycline, 30
Demoxepam, Denofungin, deoxypyridinoline, Depakote,
deprodone, Deprostil, depsidomycin, deramciclane, derma-
tan sulfate, Desciclovir, DescinoloneAcetonide, Desflurane,
Desipramine Hydrochloride, desirudin, Deslanoside, Deslo-
ratadine, deslorelin, desmopressin, Desmopressin sulfate, 35
desogestrel, Desonide, Desoximetasone, desoxoami-
odarone, Desoxy-corticosterone Acetate, detajmium bitar-
trate, Deterenol Hydrochloride, Detirelix Acetate,
Devazepide, Dexamethasone, Dexamisole, Dexbrompheni-
ramine Maleate, Dexchlorpheniramine Maleate, Dexclamol 40
Hydrochloride, Dexetimide, Dexfenfluramine Hydrochlo-
ride, dexifosfamide, Deximafen, dexketoprofen, dexloxiglu-
mide, Dexmedetomidine, Dexormaplatin, Dexoxadrol
Hydrochloride, Dexpanthenol, Dexpemedolac, Dexpropra-
nolol Hydrochloride, Dexrazoxane, dexsotalol, dextrin 45
2-sulphate, Dextroamphetamine, Dextromethorphan, Dex-
trorphan Hydrochloride, Dextrothyroxine Sodium, dexvera-
pamil, Dezaguanine, dezinamide, dezocine, Diacetolol
Hydrochloride, Diamocaine Cyclamate, Diapamide, Dia-
trizoate Meglumine, Diatrizoic Acid, Diaveridine, Diaz- 50
epam, Diaziquone, Diazoxide, Dibenzepin Hydrochloride,
Dibenzothiophene, Dibucaine, Dichliorvos, Dichloral-
phenazone, Dichlorphenamide, Dicirenone, Diclofenac,
Diclofenac Sodium, Dicloxacillin, dicranin, Dicumarol,
Dicyclomine Hydrochloride, Didanosine, didemnin B, 55
didox, Dienestrol, dienogest, Diethylcarbamazine Citrate,
diethylhomospermine, diethylnorspermine, Diethylpropion
Hydrochloride, Diethylstilbestrol, Difenoximide Hydro-
chloride, Difenoxin, Diflorasone Diacetate, Difloxacin
Hydrochloride, Difluanine Hydrochloride, Diflucortolone, 60
Diflumidone Sodium, Diflunisal, Difluprednate, Diftalone,
Digitalis, Digitoxin, Digoxin, Dihexyverine Hydrochloride,
dihydrexidine, dihydro-5-azacytidine, Dihydrocodeine
Bitartrate, Dihydroergotamine Mesylate, Dihydroestoster-
one, Dihydrostreptomycin Sulfate, Dihydrotachysterol, 65
Dilantin, Dilevalol Hydrochloride, Diltiazem Hydrochlo-
ride, Dimefadane, Dimefline Hydrochloride, Dimenhydri-
M-!
nate, Dimercaprol, Dimethadione, Dimethindene Maleate,
Dimethisterone, Dimethyl Sulfoxide, dimethylhomosper-
mine, dimethylprostaglandinAl, dimiracetam, Dimoxamine
Hydrochloride, Dinoprost, Dinoprostone, Dioxadrol Hydro-
chloride, dioxamycin, diphenhydramine, Diphenhydramine
Citrate, Diphenidol, Diphenoxylate Hydrochloride, diphe-
nylspiromustine, Dipivefin Hydrochloride, Dipivefrin,
dipliencyprone, diprafenone, dipropylnorspermine,
Dipyridamole, Dipyrithione, Dipyrone, dirithromycin, dis-
codermolide, Disobutamide, Disofenin, Disopyramide, Dis-
oxaril, disulfuram, Ditekiren, Divalproex Sodium, Dizocil-
pine Maleate, DL-methionine, Dobutamine, docarpamine,
Docebenone, Docetaxel, Doconazole, docosanol, dofetilide,
dolasetron, Donepezil, doripenem, Dorzolamide, Doxa-
zosin, doxazosin mesylate, doxycydine, Drospirenone,
Duloxetine, Dutasteride, Ebastine, ebiratide, ebrotidine,
ebselen, ecabapide, ecabet, ecadotril, ecdisteron, echicetin,
echistatin, Echothiophate Iodide, Eclanamine Maleate, Ecla-
zolast, ecomustine, Econazole, ecteinascidin 722, eculi-
zumab, edaravone, Edatrexate, edelfosine, Edifolone
Acetate, edobacomab, Edoxudine, edrecolomab, Edropho-
nium Chloride, edroxyprogesteone Acetate, Efavirenz, efe-
gatran, eflornithine, efonidipine, egualcen, Elantrine, ele-
atonin, elemene, eletriptan, elgodipine, eliprodil,
Elsamitrucin, eltenae, Elucaine, emailcalim, emedastine,
Emetine Hydrochloride, emiglitate, Emilium Tosylate,
emitefur, emoctakin, Enuricitabine, Enadoline Hydrochlo-
ride, Enailciren, enalapril, enalapril maleate, enazadrem,
Encyprate, Endralazine Mesylate, Endrysone, Enflurane,
englitazone, Enilconazole, Enisoprost, Enlimomab, Enlo-
platin, Enofelast, Enolicam Sodium, Enoxacin, enoxacin,
enoxaparin sodium, Enoxaparin Sodium, Enoximone,
Enpiroline Phosphate, Enprofylline, Enpromate, entaca-
pone, enterostatin, Enviradene, Enviroxime, Ephedrine, Epi-
cillin, Epimestrol, Epinephrine, Epinephryl Borate, Epipro-
pidine, Epirizole, epirubicin, Epitetracycline Hydrochloride,
Epithiazide, Epoetin Alfa, Epoetin Beta, Epoprostenol, Epo-
prostenol Sodium, epoxymexrenone, epristeride, Eprosar-
tan, eptastigmine, equilenin, Equilin, Erbulozole, erdosteine,
Ergoloid Mesylates, Ergonovine Maleate, Ergotamine Tar-
trate, Erlotinib, ersentilide, Ersofermin, erythritol, Erythrityl
Tetranitrate, Erythromycin, Erythropoetin, Escitalopram,
Esmolol Hydrochloride, esomeprazole, Esorubicin Hydro-
chloride, Esproquin Hydrochloride, Estazolam, Estradiol,
Estramustine, Estrazinol Hydrobromide, Estriol, Estrofu-
rate, Estrogen, Estrone, Estropipate, esuprone, Eszopiclone,
Etafedrine Hydrochloride, etanercept, Etanidazole, etan-
terol, Etarotene, Etazolate Hydrochloride, Eterobarb, etha-
cizin, Ethacrynate Sodium, Ethacrynic Acid, Ethambutol
Hydrochloride, Ethamivan, Ethanolamine Oleate, Ethehlo-
rvynol, Ethembutol hydrochloride, Ethinyl estradiol, Ethio-
dized Oil, Ethionamide, Ethonam Nitrate, Ethopropazine
Hydrochloride, Ethosuximide, Ethosuximide, Ethotoin,
Ethoxazene Hydrochloride, Ethybenztropine, Ethyl Chlo-
ride, Ethyl Dibunate, Ethylestrenol, Ethyndiol, Ethynerone,
ethynl estradiol, Ethynodiol Diacetate, Etibendazole, Etido-
caine, Etidronate Disodium, Etidronic Acid, Etifenin, Etinti-
dine Hydrochloride, etizolam, Etodolac, Etofenamate, Eto-
formin Hydrochloride, Etomidate, Etonogestrel,
Etoperidone Hydrochloride, Etoposide, Etoprine, etori-
coxib, Etoxadrol Hydrochloride, Etozolin, etrabamine, etra-
virine, Etretinate, Etryptamine Acetate, Eucatropine Hydro-
chloride, Eugenol, Euprocin Hydrochloride, eveminomicin,
Exametazime, examorelin, Exaprolol Hydrochloride,
exemestane, Exenatide, Ezetimibe, Ezetimibe, Factor VII,
fadrozole, faeriefungin, Famciclovir, Famotidine, Fampri-
dine, fantofarone, Fantridone Hydrochloride, faropenem,
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fasidotril, fasudil, fazarabine, fedotozine, Felbamate, fel-
bamate, Felbinac, Felodipine, Felypressin, Fenalamide,
Fenamole, Fenbendazole, Fenbufen, Fencibutirol, Fen-
clofenac, Fenclonine, Fenclorac, Fendosal, Fenestrel, Fen-
ethylline Hydrochloride, Fenfluramine Hydrochloride,
Fengabine, Fenimide, Fenisorex, Fenmetozole Hydrochlo-
ride, Feumetramide, Fenobam, Fenoctimine Sulfate, Feno-
fibrate, fenoldopam, Fenoprofen, Fenoterol, Fenpipalone,
Fenprinast Hydrochloride, Fenprostalene, Fenquizone, fen-
retinide, fenspiride, fentanyl, Fentanyl Citrate, Fentiazac,
Fenticlor, fenticonazole, Fenyripol Hydrochloride, fepradi-
nol, ferpifosate sodium, ferristene, ferrixan, Ferrous Sulfate,
Ferumoxides, ferumoxsil, Fetoxylate Hydrochloride, Fex-
ofenadine, fexofenadine hydrochloride, Fezolamine Fumar-
ate, Fiacitabine, Fialuridine, fibmoxef, Fibrinogen, Fil-
grastim, Filipin, Finasteride, fiorfenicol, fiorifenine,
fiosatidil, fiumecinol, fiunarizine, fiuparoxan, fiupirtine, fiu-
rithromycin, fiutrimazole, fiuvastatin, fiuvoxamine, Fla-
vodilol Maleate, flavopiridol, Flavoxate Hydrochloride, Fla-
zalone, flecamide, flerobuterol, Fleroxacin, flesinoxan,
Flestolol Sulfate, Fletazepam, flezelastine, flobufen, Floc-
tafenine, Flordipine, Flosequinan, Floxacillin, Floxuridine,
fluasterone, Fluazacort, Flubanilate Hydrochloride, Fluben-
dazole, Flucindole, Flucloronide, Fluconazole, Flucytosine,
Fludalanine, Fludarabine Phosphate, Fludazonium Chloride,
Fludeoxyglucose, Fludorex, Fludrocortisone Acetate, Flufe-
namic Acid, Flufenisal, Flumazenil, Flumequine, Flumeri-
done, Flumethasone, Flumetramide, Flumezapine, Flumi-
norex, Flumizole, Flumoxonide, Flunidazole, Flunisolide,
Flunitrazepam, Flunixin, fluocalcitriol, Fluocinolone
Acetonide, Fluocinonide, Fluocortin Butyl, Fluocortolone,
Fluorescein, fluorodaunorunicin hydrochloride, Fluorodopa,
Fluorometholone, Fluorouracil, Fluotracen Hydrochloride,
Fluoxetine, Fluoxetine hydrochloride, Fluoxymesterone,
Fluperamide, Fluperolone Acetate, Fluphenazine Decano-
ate, Fluprednisolone, Fluproquazone, Fluprostenol Sodium,
Fluquazone, Fluradoline Hydrochloride, Flurandrenolide,
Flurazepam Hydrochloride, Flurbiprofen, Fluretofen, Flu-
orocitabine, Fluorofamide, Fluorogestone Acetate, Fluoro-
thyl, Fluoroxene, Fluspiperone, Fluspirilene, Fluticasone,
Fluticasone Propionate, Flutroline, Fluvastatin, Fluvastatin
Sodium, Fluzinamide, Folic Acid, Follicle regulatory pro-
tein, Folliculostatin, Follitropin alfa, Follitropin beta,
Fomepizole, Fonazine Mesylate, forasartan, forfenimex, for-
fenirmex, formestane, Formocortal, formoterol, Fosarilate,
Fosazepam, Foscamet Sodium, fosfomycin, Fosfonet
Sodium, fosinopril, Fosinopril sodium, Fosinoprilat, fosphe-
nyloin, Fosquidone, Fostedil, fostriecin, fotemustine,
Fuchsin, Fumoxicillin, Fungimycin, Furaprofen, Furazoli-
done, Furazolium Chloride, Furegrelate Sodium, Furobufen,
Furodazole, Furosemide, Fusidate Sodium, Fusidic Acid,
Gabapentin, Gadobenate Dimeglumine, gadobenic acid,
gadobutrol, Gadodiamide, gadolinium texaphyrin, Gado-
pentetate Dimegiumine, gadoteric acid, Gadoteridol, Gado-
versetamide, galantamine, galdansetron, Galdansetron
Hydrochloride, Gallamine Triethiodide, gallium nitrate, gal-
lopamil, galocitabine, Gamfexine, gamolenic acid, Ganci-
clovir, ganirelix, Gemcadiol, Gemcitabine, Gemeprost,
Gemfibrozil, Gentamicin Sulfate, Gentian Violet, gepirone,
Gestaclone, Gestodene, Gestonorone Caproate, Gestrinone,
Gevotroline Hydrochloride, girisopam, glargine insulin,
glaspimod, Glatiramer, glaucocalyxin A, Glemanserin, Gli-
amilide, Glibornuride, Glicetanile Sodium, Glifiumide,
Glimepiride, Glipizide, Gloximonam, Glucagon, glutapy-
rone, Glutethimide, Glyburide, glycopine, glycopril, Glyco-
pyrrolate, Glyhexamide, Glymidine Sodium, Glyoctamide,
Glyparamide, Gold Au-198, Gonadoctrinins, Gonadorelin,
kf,
Gonadotropins, Goserelin, Gramicidin, Granisetron, gre-
pafioxacin, Griseofulvin, Guaiapate, Guaithylline, Gua-
nabenz, Guanabenz Acetate, Guanadrel Sulfate, Guancy-
dine, Guanethidine Monosulfate, Guanfacine
5 Hydrochloride, Guanisoquin Sulfate, Guanoclor Sulfate,
Guanoctine Hydrochloride, Guanoxabenz, Guanoxan Sul-
fate, Guanoxyfen Sulfate, Gusperimus Trihydrochloride,
Halazepam, Halcinonide, halichondrin B, Halobetasol Pro-
pionate, halofantrine, Halofantrine Hydrochloride,
io Halofenate, Halofuginone Hydrobromide, halomon,
Halopemide, Haloperidol, halopredone, Haloprogesterone,
Haloprogin, Halothane, Halquinols, Hamycin, hatomamicin,
hatomarubigin A, hatomarubigin B, hatomarubigin C, hato-
marubigin D, Heparin Sodium, hepsulfam, heregulin, Heta-
15 cillin, Heterooium Bromide, Hexachlorophene: Hydrogen
Peroxide, Hexafluorenium Bromide, hexamethylene bisac-
etamide, Hexedine, Hexobendine, Hexoprenaline Sulfate,
Hexylresorcinol, Histamine Phosphate, Histidine, Histoplas-
min, Histrelin, histrelin acetate, Homatropine Hydrobro-
20 wide, Hoquizil Hydrochloride, Human chorionic gonado-
tropin, Human growth hormone, Hycanthone, Hydralazine
Hydrochloride, Hydralazine Polistirex, Hydrochlorothiaz-
ide, Hydrocodone Bitartrate, Hydrocortisone, Hydroflume-
thiazide, Hydromorphone Hydrochloride, Hydroxyamphet-
25 amine Hydrobromide, Hydroxychloroquine Sulfate,
Hydroxyphenamate, Hydroxyprogesterone Caproate,
Hydroxyurea, Hydroxyzine Hydrochloride, Hymecromone,
Hyoscyamine, hypericin, Ibafloxacin, Ibandronate, ibo-
gaine, Ibopam, ibudilast, Ibufenac, Ibuprofen, Ibutilide
so Fumarate, Icatibant Acetate, Ichthammol, Icotidine, idaru-
bicin, idoxifene, Idoxuridine, idramantone, Ifetroban, Ifos-
famide, Ilepeimide, illimaquinone, ilmofosin, ilomastat, Ilo-
nidap, iloperidone, iloprost, Imafen Hydrochloride,
Imatinib, Imazodan Hydrochloride, imidapril, imidazenil,
35 imidazoacridone, Imidecyl Iodine, Imidocarb Hydrochlo-
ride, Imidoline Hydrochloride, Imidurea, Imiglucerase, Imi-
loxan Hydrochloride, Imipenem, Imipramine Hydrochlo-
ride, imiquimod, Impromidine Hydrochloride, Indacrinone,
Indapamide, Indecamide Hydrochloride, Indeloxazine
4o Hydrochloride, Indigotindisulfonate Sodium, indinavir,
Indinavir sulfate, Indocyanine Green, Indolapril Hydrochlo-
ride, Indolidan, indometacin, Indomethacin Sodium, Indo-
profen, indoramin, Indorenate Hydrochloride, Indoxole,
Indriline Hydrochloride, infliximab, inocoterone, inogatran,
45 inolimomab, Inositol Niacinate, Insulin, Interferon beta-la,
Intrazole, Intriptyline Hydrochloride, iobenguane, Ioben-
zamic Acid, iobitridol, Iodine, iodoamiloride, iododoxoru-
bicin, iofratol, iomeprol, iopentol, iopromide, iopyrol, iotri-
side, ioxilan, ipazilide, ipenoxazone, ipidacrine, Ipodate
50 Calcium, ipomeanol, Ipratropium, Ipratropium Bromide,
ipriflavone, Iprindole, Iprofenin, Ipronidazole, Iproplatin,
Iproxamine Hydrochloride, ipsapirone, irbesartan, irinote-
can, irloxacin, iroplact, irsogladin, Irtemazole, isalsteine,
Isamoxole, isbogrel, Isepamicin, isobengazole, Isobutam-
55 ben, Isocarboxazid, Isoconazole, Isoetharine, isofloxythe-
pin, Isoflupredone Acetate, Isoflurane, Isofluorophate, iso-
homohalicondrin B, Isoleucine, Isomazole Hydrochloride,
Isomylamine Hydrochloride, Isoniazid, Isopropamide
Iodide, Isopropyl Alcohol, isopropyl unoprostone, Isopro-
60 terenol Hydrochloride, Isosorbide, Isosorbide Mononitrate,
Isotiquimide, Isotretinoin, Isoxepac, Isoxicam, Isoxsuprine
Hydrochloride, isradipine, itameline, itasetron, Itazigrel, ito-
pride, Itraconazole, Ivermectin, ixabepilone, jasplakinolide,
Jemefloxacin, Jesopitron, Josamycin, kahalalide F, Kala-
65 fungin, Kanamycin Sulfate, ketamine, Ketanserin, Ketazo-
cine, Ketazolam, Kethoxal, Ketipramine Fumarate, Keto-
conazole, Ketoprofen, Ketorfanol, ketorolac, Ketotifen
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Fumarate, Kitasamycin, Labetalol Hydrochloride, Laci-
dipine, lacidipine, lactitol, lactivicin, Lactobionate, laennec,
lafutidine, 1-alphahydroxyvitamin D2, lamellarin-N triac-
etate, lamifiban, Lamivudine, Lamotrigine, lanoconazole,
Lanoxin, lanperisone, lanreotide, lanreotide acetate, Lanso-
prazole, lapatinib, laropiprant, latanoprost, lateritin, lauro-
capram, Lauryl Isoquinolinium Bromide, Lavoltidine Suc-
cinate, lazabemide, Lecimibide, leinamycin, lemildipine,
leminoprazole, lenercept, Leniquinsin, lenograstim, Lenper-
one, lentinan sulfate, leptin, leptolstatin, lercanidipine, Ler-
gotrile, lerisetron, Letimide Hydrochloride, letrazuril, letro-
zole, Leucine, leucomyzin, leuprolide, Leuprolide Acetate,
leuprorelin, Levalbuterol, Levamfetamine Succinate,
levamisole, Levdobutamine Lactobionate, Leveromakalim,
levetiracetam, Leveycloserine, levobetaxolol, levobunolol,
levobupivacaine, levocabastine, levocarnitine, levocetiriz-
ine, levocetirizine dhydrochloride, Levodopa, levodro-
propizine, levofloxacin, Levofuraltadone, Levoleucovorin
Calcium, Levomethadyl Acetate, Levomethadyl Acetate
Hydrochloride, levomoprolol, Levonantradol Hydrochlo-
ride, Levonordefrin, Levonorgestrel, Levopropoxyphene
Napsylate, Levopropylcillin Potassium, levormeloxifene,
Levorphanol Tartrate, levosimendan, levosulpiride, Levo-
thyroxine, Levothyroxine Sodium, Levoxadrol Hydrochlo-
ride, Lexipafant, Lexithromycin, liarozole, Libenzapril, Lid-
amidine Hydrochloride, Lidocaine, Lidofenin, Lidoflazine,
Lifarizin, Lifibrate, Lifibrol, Linarotene, Lincomycin, Lin-
ezolid, Linogliride, Linopirdine, linotroban, linsidomine,
lintitript, lintopride, Liothyronine I-125, liothyronine
sodium, Liotrix, lirexapride, Lisdexamfetamine Dimesylate,
lisinopril, Lispro insulin, lissoclinamide, Lixazinone Sul-
fate, lobaplatin, Lobenzarit Sodium, Lobucavir, locarmate
Meglumine, locarmic Acid, locetamic Acid, lodamide,
Lodelaben, lodipamide Meglumine, lodixanol, Iodoantipy-
rine I-131, Iodocholesterol I-131, Iodohippurate Sodium
I-131, Iodopyracet I-125, Iodoquinol, Iodoxamate Meglu-
mine, lodoxamide, IodoxamieAcid, Lofemizole Hydrochlo-
ride, Lofentanil Oxalate, Lofepramine Hydrochloride, lofe-
tamine Hydrochloride I-123, Lofexidine Hydrochloride,
loglicic Acid, loglucol, loglucomide, loglycamic Acid, logu-
lamide, lohexyl, lombricine, Lomefloxacin, lomerizine,
lomethin I-125, Lometraline Hydrochloride, lometrexol,
Lomofungin, Lomoxicam, Lomustine, Lonapalene, lonazo-
lac, lonidamine, lopamidol, lopanoic Acid, Loperamide
Hydrochloride, lophendylate, Lopinavir, loprocemic Acid,
lopronic Acid, lopydol, lopydone, loracarbef, Lorajmine
Hydrochloride, loratadine, Lorazepam, Lorbamate, Lorc-
amide Hydrochloride, Loreclezole, Loreinadol, lorglumide,
Lormetazepam, Lomoxicam, lornoxicam, Lortalamine,
Lorzafone, losartan, Losartan potassium, losefamic Acid,
loseric Acid, losigamone, losoxantrone, losulamide Meglu-
mine, Losulazine Hydrochloride, losumetic Acid, lotasul,
loteprednol, lotetric Acid, lothalamate Sodium, lothalamic
Acid, lotrolan, lotroxic Acid, lovastatin, loversol, loviride,
loxagiate Sodium, loxaglate Meglumine, loxaglic Acid,
Loxapine, Loxoribine, loxotrizoic Acid, lubeluzole, Lucan-
thone Hydrochloride, Lufironil, Lurosetron Mesylate, lurto-
tecan, lutetium, Lutrelin Acetate, luzindole, Lyapolate
Sodium, Lycetamine, lydicamycin, Lydimycin, Lynestrenol,
Lypressin, Lysine, lysofylline, lysostaphin, Maduramicin,
Mafenide, magainin 2 amide, Magnesium Salicylate, Mag-
nesium Sulfate, magnolol, maitansine, Malethamer, mallo-
toaponin, mallotochromene, Malotilate, malotilate, manga-
fodipir, manidipine, maniwamycin A, Mannitol,
mannostatin A, manumycin E, manumycin F, mapinastine,
Maprotiline, maraviroc, marimastat, Marinol, Masoprocol,
maspin, massetolide, Maytansine, Mazapertine Succiniate,
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Mazindol, Mebendazole, Mebeverine Hydrochloride,
Mebrofenin, Mebutamate, Mecamylamine Hydrochloride,
Mechlorethamine Hydrochloride, meclizine hydrochloride,
Meclocycline, Meclofenamate Sodium, Mecloqualone,
5 Meclorisone Dibutyrate, Medazepam Hydrochloride,
Medorinone, Medrogestone, Medroxalol, Medroxyproges-
terone, Medrysone, Meelizine Hydrochloride, Mefenamic
Acid, Mefenidil, Mefenorex Hydrochloride, Mefexamide,
Mefloquine Hydrochloride, Mefruside, Megalomicin Potas-
io sium Phosphate, Megestrol Acetate, Meglumine, Meglutol,
Melengestrol Acetate, Meloxicam, Melphalan, Memantine,
Memotine Hydrochloride, Menabitan Hydrochloride,
Menoctone, menogaril, Menotropins, Meobentine Sulfate,
Mepartricin, Mepenzolate Bromide, Meperidine Hydrochlo-
15 ride, Mephentermine Sulfate, Mephenyloin, Mephobarbital,
Mepivacaine Hydrochloride, Meprobamate, Meptazinol
Hydrochloride, Mequidox, Meralein Sodium, merbarone,
Mercaptopurine, Mercufenol Chloride, Merisoprol, Mero-
penem, Mesalamine, Meseclazone, Mesoridazine, Mester-
20 olone, Mestranol, Mesuprine Hydrochloride, Metalol
Hydrochloride, Metaproterenol Polistirex, Metaraminol
Bitartrate, Metaxalone, Meteneprost, meterelin, Metformin,
Methacholine Chloride, Methacycline, methadone, Meth-
adyl Acetate, Methalthiazide, Methamphetamine Hydro-
25 chloride, Methaqualone, Methazolamide, Methdilazine,
Methenamine, Methenolone Acetate, Methetoin, Methicillin
Sodium, Methimazole, methioninase, Methionine, Methisa-
zone, Methixene Hydrochloride, Methocarbamol, Metho-
hexital Sodium, Methopholine, Methotrexate, Methotrime-
30 prazine, methoxatone, methoxy polyethylene glycol-epoetin
beta, Methoxyflurane, Methsuximide, Methyclothiazide,
Methyl Palmoxirate, Methylatropine Nitrate, Methylbenze-
thonium Chloride, Methyldopa, Methyldopate Hydrochlo-
ride, Methylene Blue, Methylergonovine Maleate, methyl-
35 histamine, methylinosine monophosphate,
Methylphenidate, Methylprednisolone, Methyltestosterone,
Methynodiol Diacelate, Methysergide, Methysergide
Maleate, Metiamide, Metiapine, Metioprim, metipamide,
Metipranolol, Metizoline Hydrochloride, Metkephamid
40 Acetate, metoclopramide, Metocurine Iodide, Metogest,
Metolazone, Metopimazine, Metoprine, Metoprolol, Meto-
prolol tartrate, Metouizine, metrifonate, Metrizamide,
Metrizoate Sodium, Metronidazole, Meturedepa,
Metyrapone, Metyrosine, Mexiletine Hydrochloride,
45 Mexrenoate Potassium, Mezlocillin, Mianserin Hydrochlo-
ride, mibefradil, Mibefradil Dihydrochloride, Mibolerone,
michellamine B, Miconazole, microcolinA, Midaflur, Mida-
zolam Hydrochloride, midodrine, mifepristone, Mifobate,
miglitol, milacemide, milameline, mildronate, Milenperone,
50 Milipertine, milnacipran, Milrinone, miltefosine, Mimbane
Hydrochloride, minaprine, Minaxolone, Minocromil, Mino-
cycline, Minocycline hydrochloride, Minoxidil, Mioflazine
Hydrochloride, miokamycin, mipragoside, mirfentanil,
mirimostim, Mirincamycin Hydrochloride, Mirisetron
55 Maleate, Mirtazapine, Misonidazole, Misoprostol, Mitindo-
mide, Mitocarcin, Mitocromin, Mitogillin, mitoguazone,
mitolactol, Mitomalcin, Mitomycin, mitonafide, Mitosper,
Mitotane, mitoxantrone, mivacurium chloride, mivazerol,
mixanpril, Mixidine, mizolastine, mizoribine, Moclobe-
60 wide, modafinil, Modaline Sulfate, Modecamide, moexipril,
mofarotene, Mofegiline Hydrochloride, mofezolac, molgra-
mostim, Molinazone, Molindone Hydrochloride, Molsidom-
ine, mometasone, Monatepil Maleate, Monensin, Monoc-
tanoin, montelukast, Montelukast Sodium, montirelin,
65 mopidamol, moracizine, Morantel Tartrate, Moricizine,
Morniflumate, Morphine, Morrhuate Sodium, mosapramine,
mosapride, motilide, Motretinide, Moxalactam Disodium,
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Moxazocine, Moxifloxacin, moxiraprine, Moxnidazole,
moxonidine, Mumps Skin Test Antigen, Muzolimine,
mycaperoxide B, Mycophenolate mofetil, Mycophenolic
Acid, myriaporone, Nabazenil, Nabilone, Nabitan Hydro-
chloride, Naboctate Hydrochloride, Nabumetone, N-acetyl-
dinaline, Nadide, nadifloxacin, Nadolol, nadroparin cal-
cium, nafadotride, nafamostat, nafarelin, Nafcillin Sodium,
Nafenopin, Nafimidone Hydrochloride, Naflocort, Nafom-
ine Malate, Nafoxidine Hydrochloride, Nafronyl Oxalate,
Naftifine Hydrochloride, naftopidil, naglivan, nagrestip,
Nalbuphine Hydrochloride, Nalidixate Sodium, Nalidixic
Acid, nalmefene, Nalmexone Hydrochloride, naloxone, Nal-
trexone, Namoxyrate, Nandrolone Phenpropionate, Nant-
radol Hydrochloride, Napactadine Hydrochloride, napadisi-
late, Napamezole Hydrochloride, napaviin, Naphazoline
Hydrochloride, naphterpin, Naproxen, Naproxen sodium,
Naproxol, napsagatran, Naranol Hydrochloride, Narasin,
naratriptan, nartograstim, nasaruplase, natalizumab,
Natamycin, nateplase, Naxagolide Hydrochloride, Nebiv-
olol, Nebramycin, nedaplatin, Nedocromil, Nefazodone
Hydrochloride, Neflumozide Hydrochloride, Nefopam
Hydrochloride, Nelezaprine Maleate, Nemazoline Hydro-
chloride, nemorubicin, Neomycin Palmitate, Neostigmine
Bromide, neridronic acid, Netilmicin Sulfate, Neutramycin,
Nevirapin Nexeridine Hydrochloride, Niacin, Nibroxane,
Nicardipine Hydrochloride, Nicergoline, Niclosamide, Nic-
orandil, Nicotinamide, Nicotinyl Alcohol, Nifedipine,
Nifirmerone, Nifluridide, Nifuradene, Nifuraldezone, Nifu-
ratel, Nifuratrone, Nifurdazil, Nifurimide, Nifurpirinol,
Nifurquinazol, Nifurthiazole, Nifurtimox, nilotinib, nilo-
tinib hydrochloride monohydrate, nilutamide, Nilvadipine,
Nimazone, Nimodipine, niperotidine, niravoline, Nirida-
zole, nisamycin, Nisbuterol Mesylate, raisin, Nisobamate,
Nisoldipine, Nisoxetin Nisterime Acetate, Nitarsone, nita-
zoxanide, nitecapone, Nitrafudam Hydrochloride, Nitrala-
mine Hydrochloride, Nitramisole Hydrochloride, Nitraze-
pam, Nitrendipine, Nitrocydine, Nitrodan, Nitrofurantoin,
Nitrofurazone, Nitroglycerin, Nitromersol, Nitromide,
Nitromifene Citrate, Nitrous Oxide, nitroxide antioxidant,
nitrullyn, Nivazol, Nivimedone Sodium, Nizatidine,
Noberastine, Nocodazole, Nogalamycin, Nolinium Bro-
mide, Nomifensine Maleate, Noracymethadol Hydrochlo-
ride, Norbolethone, Norepinephrine Bitartrate, Norethin-
drone, Norethynodrel, Norfurane, Norfloxacin,
Norgestimate, Norgestomet, Norgestrel, Nortriptyline
Hydrochloride, Noscapine, Novobiocin Nylestriol, Nystatin,
Obidoxime Chloride, Ocaperidone, Ocfentanil Hydrochlo-
ride, Ocinaplon, Octanoic Acid, Octazamide, Octenidine
Hydrochloride, Octodrine, Octreotide, Octriptyline Phos-
phate, Ofloxacin, Ofornine, okicenone, Olanzepine, Olme-
sartan, olmesartan medoxomil, olopatadine, olopatadine
hydrochloride, olprinone, olsalazine, Olsalazine Sodium,
Olvanil, Omalizumab, Omega-3 acid ethyl esters, omepra-
zole, onapristone, ondansetron, Ontazolast, Oocyte Opipra-
mol Hydrochloride, oracin, Orconazole Nitrate, Orgotein,
Orlislat, Ormaplatin, Ormetoprim, Ornidazole, Orpanoxin,
Orphenadrine Citrate, osaterone, Oseltamivir, otenzepad,
Oxacillin Sodium, Oxagrelate, oxaliplatin, Oxamarin
Hydrochloride, oxamisole, Oxamniquine, oxandrolone,
Oxantel Pamoate, Oxaprotiline Hydrochloride, Oxaprozin,
Oxarbazole, Oxatomide, oxaunomycin, Oxazepam, oxcar-
bazepine, Oxendolone, Oxethazaine, Oxetorone Fumarate,
Oxfendazole, Oxfenicine, Oxibendazole, oxiconazole, Oxi-
dopamine, Oxidronic Acid, Oxifungin Hydrochloride,
Oxilorphan, Oximonam, Oximonam Sodium, Oxiperomide,
oxiracetam, Oxiramide, Oxisuran, Oxmetidine Hydrochlo-
ride, oxodipine, Oxogestone Phenpropionate, Oxolinic
40
Acid, Oxprenolol Hydrochloride, Oxtriphylline, Oxybu-
tynin Chloride, Oxychlorosene, Oxycodone, oxycodone
hydrochloride, Oxymetazoline Hydrochloride,
oxymetholone, Oxymorphone Hydrochloride, Oxypertine,
5 Oxyphenbutazone, Oxypurinol, Oxytetracycline, Oxytocin,
ozagrel, Ozlinone, Paclitaxel, palauamine, Paldimycin, pali-
navir, Palivizumab, palmitoylrhizoxin, Palmoxirate Sodium,
pamaqueside, Pamatolol Sulfate, pamicogrel, Pamidronate
Disodium, pamidronic acid, Panadiplon, panamesine,
io panaxytriol, Pancopride, Pancuronium Bromide,
panipenem, pannorin, panomifene, pantethine, pantopra-
zole, Papaverine Hydrochloride, parabactin, paracetamol,
Parachlorophenol, Paraldehyde, Paramethasone Acetate,
Paranyline Hydrochloride, Parapenzolate Bromide, Pararo-
15 saniline Pamoate, Parbendazole, Parconazole Hydrochlo-
ride, Paregoric, Pareptide Sulfate, Pargyline Hydrochloride,
parnaparin sodium, Paromomycin Sulfate, Paroxetine, par-
oxetine hydrochloride, parthenolide, Partricin, Paulomycin,
pazelliptine, Pazinaclone, Pazoxide, pazufloxacin, pefloxa-
20 cin, pegaspargase, Pegorgotein, Pegylated interferon alfa-
2a, Pelanserin Hydrochloride, peldesine, Peliomycipelretin,
Perinone Hydrochloride, Pemedolac, Pemerid Nitrate,
Pemetrexed, pemirolast, Pemoline, Penamecillin, Penbu-
tolol Sulfate, Penciclovir, Penfluridol, Penicillamine, Peni-
25 cillin G Benzathine, Penicillin G Potassium, Penicillin G
Procaine, Penicillin G Sodium, Penicillin V Hydrabamine,
Penicillin V Benzathine, Penicillin V Potassium, Pentabam-
ate, Pentaerythritol Tetranitrate, pentafuside, pentamidine,
pentamorphone, Pentamustine, Pentapiperium Methylsul-
30 fate, Pentazocine, Pentetic Acid, Pentiapine Maleate, pen-
tigetide, Pentisomicin, Pentizidone Sodium, Pentobarbital,
Pentomone, Pentopril, pentosan, pentostatin, Pentoxifylline,
Pentrinitrol, pentrozole, Peplomycin Sulfate, Pepstatin, per-
flubron, perfofamide, Perfosfamide, pergolide, Perhexyline
35 Maleate, perillyl alcohol, Perindopril, perindoprilat, Per-
lapin Permethrin, perospirone, Perphenazine, Phenacemide,
phenaridine, phenazinomycin, Phenazopyridine Hydrochlo-
ride, Phenbutazone Sodium Glycerate, Phencarbamide,
Phencyclidine Hydrochloride, Phendimetrazine Tartrate,
40 Phenelzine Sulfate, Phenformin, Phenmetrazine Hydrochlo-
ride, Phenobarbital, Phenoxybenzamine Hydrochloride,
Phenprocoumon, phenaerine, phensuccinal, Phensuximide,
Phentermine, Phentermine Hydrochloride, phentolamine
mesilate, Phentoxifylline, Phenyl Aminosalicylate, pheny-
45 lacetate, Phenylalanine, phenylalanylketoconazole, Phe-
nylbutazone, Phenylephrine Hydrochloride, Phenylpropa-
nolamine Hydrochloride, Phenylpropanolamine Polistirex,
Phenyramidol Hydrochloride, Phenyloin, Phenyloin
sodium, Physostigmine, picenadol, picibanil, Picotrin
5o Diolamine, picroliv, picumeterol, pidotimod, Pifarnine,
Pilocarpine, pilsicamide, pimagedine, Pimetine Hydrochlo-
ride, pimilprost, Pimobendan, Pimozide, Pinacidil, Pinado-
line, Pindolol, pinnenol, pinocebrin, Pinoxepin Hydrochlo-
ride, pioglitazone, Pipamperone, Pipazethate, pipecuronium
55 bromide, Piperacetazine, Piperacillin, Piperacillin Sodium,
Piperamide Maleate, piperazinc, Pipobroman, Piposulfan,
Pipotiazine Palmitate, Pipoxolan Hydrochloride, Piprozolin,
Piquindone Hydrochloride, Piquizil Hydrochloride, Pirac-
etam, Pirandamine Hydrochloride, pirarubicin, Pirazmonam
60 Sodium, Pirazolac, Pirbenicillin Sodium, Pirbuterol Acetate,
Pirenperone, Pirenzepine Hydrochloride, piretanide, Pirfeni-
done, Piridicillin Sodium, Piridronate Sodium, Piriprost,
piritrexim, Pirlimycin Hydrochloride, pirlindole, pirmagrel,
Pirmenol Hydrochloride, Pirnabine, Piroctone, Pirodavir,
65 pirodomast, Pirogliride Tartrate, Pirolate, Pirolazamide,
Piroxantrone Hydrochloride, Piroxicam, Piroximone, Pir-
profen, Pirquinozol, Pirsidomine, Pivampicillin Hydrochlo-
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ride, Pivopril, Pizotyline, placetin A, Plicamycin, Plomes-
tane, Pobilukast Edamine, Podofilox, Poisonoak Extract,
Poldine Methylsulfate, Poliglusam, Polignate Sodium, Poly-
myxin B Sulfate, Polythiazide, Ponalrestat, Porfimer
Sodium, Porfiromycin, Potassium Chloride, Potassium
Iodide, Potassium Permanganate, Povidone-Iodine, Prac-
tolol, Pralidoxime Chloride, Pramipexole, Pramiracetam
Hydrochloride, Pramoxine Hydrochloride, Pranolium Chlo-
ride, Pravadoline Maleate, Pravastatin, Pravastatin sodium,
Prazepam, Prazosin, Prazosin Hydrochloride, Prednazate,
Prednicarbate, Prednimustine, Prednisolone, prednisolone
quetiapine fumerate, Prednisone, Prednival, Pregabalin,
Pregnenolone Succiniate, Prenalterol Hydrochloride, Pre-
nylamine, Pridefine Hydrochloride, Prifelone, Prilocalne
Hydrochloride, Prilosec, Primaquine Phosphate, Primidolol,
Primidone, Prinivil, Prinomide Tromethamine, Prinoxodan,
pritosufloxacin, Prizidilol Hydrochloride, Proadifen Hydro-
chloride, Probenecid, Probicromil Calcium, Probucol, Pro-
cainamide Hydrochloride, Procaine Hydrochloride, Procar-
bazine Hydrochloride, Procaterol Hydrochloride,
Prochlorperazine, Procinonide, Proclonol, Procyclidine
Hydrochloride, Prodilidine Hydrochloride, Prodolic Acid,
Profadol Hydrochloride, Progabide, Progesterone, Proglu-
mide, Proinsulin (human), Proline, Prolintane Hydrochlo-
ride, Promazine Hydrochloride, Promethazine, Promethaz-
ine hydrochloride, Propafenone Hydrochloride,
propagermanium, Propanidid, Propantheline Bromide,
Proparacaine Hydrochloride, Propatyl Nitrate, propentofyl-
line, Propenzolate Hydrochloride, Propikacin, Propiomaz-
ine, Propionic Acid, propionylcamitine, propiram, propiram,
propiverine, Propofol, Proponolol hydrochloride, Propoxy-
caine Hydrochloride, Propoxyphene Hydrochloride, Propra-
nolol Hydrochloride, Propulsid, propylbi s-acri done, Propy-
lhexedrine, Propyliodone, Propylthiouracil, Proquazone,
Prorenoate Potassium, Proroxan Hydrochloride, Proscillari-
din, Prostalene, prostratin, Protamine Sulfate, protegrin,
Protirelin, Protriptyline Hydrochloride, Proxazole, Prox-
azole Citrate, Proxicromil, Proxorphan Tartrate, prulifloxa-
cin, pseudoephedrine, Pseudophedrine hydrochloride, Puro-
mycin, Pyrabrom, Pyrantel Pamoate, Pyrazinamide,
Pyrazofurin, pyrazoloacridine, Pyridostigmine Bromide,
Pyridoxine hydrochloride, Pyrilamine Maleate, Pyrimeth-
amine, Pyrinoline, Pyrithione Sodium, Pyrithione Zinc,
Pyrovalerone Hydrochloride, Pyroxamine Maleate, Pyrro-
caine, Pyrroliphene Hydrochloride, PyrroInitrin, Pyrvinium
Pamoate, Quadazocine Mesylate, Quazepam, Quazinone,
Quazodine, Quazolast, quetiapine, quetiapine fumarate, qui-
flapon, quinagolide, Quinaldine Blue, quinapril, Quinapril
hydrochloride, Quinazosin Hydrochloride, Quinbolone,
Quinctolate, Quindecamine Acetate, Quindonium Bromide,
Quinelorane Hydrochloride, Quinestrol, Quinfamide,
Quingestanol Acetate, Quingestrone, Quinidine Gluconate,
Quinelorane Hydrochloride, Quinine Sulfate, Quinpirole
Hydrochloride, Quinterenol Sulfate, Quinuclium Bromide,
Quinupristin, Quipazine Maleate, Rabeprazole, Rabeprazole
Sodium, Racephenicol, Racepinephrine, Rafoxanide, Rali-
toline, raloxifene, raltegravir, raltitrexed, ramatroban,
Ramipril, Ramoplann, ramosetron, ranelic acid, Ranmycin,
Rantidine, Rantidine hydrochloride, ranolazine, Rauwolfia
Serpentina, recainam, Recainam Hydrochloride, Reclaze-
pam, Recombinant factor VIII, regavirumab, Regramostim,
Relaxin, Relomycin, Remacemide Hydrochloride, Remifen-
tanl Hydrochloride, Remiprostol, Remoxipride, Repirinast,
Repromicin, Reproterol Hydrochloride, Reserpine, resin-
feratoxin, Resorcinol, retapamulin, retelliptine demethyl-
ated, reticulon, reviparin sodium, revizinone, rhenium
etidronate, rhizoxin, RI retinamide, Ribaminol, Ribavirin,
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Riboprine, ricasetron, Ridogrel, Rifabutin, Rifametane,
Rifamexil, Rifamide, Rifampin, Rifapentine, Rifaximin,
rilopirox, Riluzole, rimantadine, Rimcazole Hydrochloride,
Rimexolone, Rimiterol Hydrobromide, Rimonabant, rimo-
5 progin, riodipine, Rioprostil, Ripazepam, ripisartan, Rise-
dronate, Risedronate Sodium, risedronic acid, Risocaine,
Risotilide Hydrochloride, rispenzepine, Risperdal, Risperi-
done, Ritanserin, ritipenem, Ritodrine, Ritolukast, ritonavir,
rituximab, rivastigmine, rivastigmine tartrate, Rizatriptan,
io rizatriptan benzoate, Rocastine Hydrochloride, Rocuronium
Bromide, Rodocaine, Roflurane, Rogletimide, rohitukine,
rokitamycin, Roletamicide, Rolgamidine, Rolicyprine,
Rolipram, Rolitetracycline, Rolodine, Romazarit, romurtide,
Ronidazole, Ropinirole, Ropitoin Hydrochloride, ropiva-
15 caine, Ropizine, roquinimex, Rosaramicin, rosiglitazone,
Rosiglitazone maleate, Rosoxacin, Rosuvastatin, Rotavirus
vaccine, rotigotine, Rotoxamine, roxaitidine, Roxarsone,
roxindole, roxithromycin, rubiginone B1, ruboxyl, rufloxa-
cin, rupatidine, Rutamycin, ruzadolane, Sabeluzole, safin-
20 gol, safironil, saintopin, salbutamol, Salbutamol sulfate,
Salcolex, Salethamide Maleate, Salicyl Alcohol, Salicylam-
ide, Salicylate Meglumine, Salicylic Acid, Salmeterol, Sal-
nacediin, Salsalate, sameridine, sampatrilat, Sancycline,
sanfetrinem, Sanguinarium Chloride, Saperconazole,
25 saprisartan, sapropterin, sapropterin dihydrochloride, saqui-
navir, Sarafloxacin Hydrochloride, Saralasin Acetate, sar-
cophytol A, sargramostim, Sarmoxicillin, Sarpicillin, sar-
pogrelate, saruplase, saterinone, satigrel, satumomab
pendetide, Scopafungin, Scopolamine Hydrobromide,
30 Scrazaipine Hydrochloride, Secalciferol, Secobarbital, Seel-
zone, segiline, Seglitide Acetate, Selegiline Hydrochloride,
Selenium Sulfide, Selenomethionine Se-75, Selfotel, sema-
tilide, semduramicin, semotiadil, semustine, Sepazonium
Chloride, Seperidol Hydrochloride, Seprilose, Seproxetine
35 Hydrochloride, Seractide Acetate, Sergolexole Maleate, Ser-
ine, Sermetacin, Sermorelin Acetate, sertaconazole, sertin-
dole, sertraline, sertraline hydrochloride, S-ethynyluracil,
setiptiline, Setoperone, Sevelamer, sevirumab, sevoflurane,
sezolamide, Sibopirdine, Sibutramine Hydrochloride, Silan-
4o drone, Sildenafil, sildenafil citrate, silipide, silteplase, Silver
Nitrate, simendan, Simtrazene, Simvastatin, Sincalide, Sine-
fungin, sinitrodil, sinnabidol, sipatrigine, sirolimus, Sisomi-
cin, Sitagliptin, Sitogluside, sizofiran, sobuzoxane, Sodium
Amylosulfate, Sodium Iodide I-123, Sodium Nitroprusside,
45 Sodium Oxybate, sodium phenylacetate, Sodium Salicylate,
Sodium valproate, Solifenacin, solverol, Solypertine Tar-
trate, Somalapor, Somantadine Hydrochloride, somatome-
din B, somatomedin C, Somatostatin, somatrem, somatro-
pin, Somenopor, Somidobove, Sorbinil, Sorivudine, sotalol,
50 Soterenol Hydrochloride, Sparfioxacin, Sparfosate Sodium,
sparfosic acid, Sparsomy, Sparteine Sulfate, Spectinomycin
Hydrochloride, spicamycin D, Spiperone, Spiradoline
Mesylate, Spiramycin, Spirapril Hydrochloride, Spiraprilat,
Spirogermanum Hydrochloride, Spiromustine, Spironolac-
55 tone, Spiroplatin, Spiroxasone, splenopentin, spongistatin,
Sprodiamide, squalamine, Stallimycin Hydrochloride, Stan-
nous Pyrophosphate, Stannous Sulfur Colloid, Stanozolol,
Statolon, staurosporine, stavudine, Steflimycin, Stenbolone
Acetate, stepronn, Stilbazium Iodide, Stilonum Iodide,
60 stipiamide, Stiripentol, stobadine, Streptomycin Sulfate,
Streptoncozid, Streptongrin, Streptozocin, Strontium Chlo-
ride Sr-89, succibun, Succimer, Succinylcholine Chloride,
Sucralfate, Sucrosofate Potassium, Sudoxicam, Sufentanl,
Sufotidine, Sulazepam, Sulbactam Pivoxil, Sulconazole
65 Nitrate, Sulfabenz, Sulfabenzamide, Sulfacetamide, Sul-
facytine, Sulfadiazine, Sulfadoxine, Sulfalene, Sulfamera-
zine, Sulfameter, Sulfamethazine, Sulfamethizole, Sulfame-
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thoxazole, Sulfamonomethoxine, Sulfamoxole, Sulfanilate
Zinc, Sulfanitran, sulfasalazine, Sulfasomizole, Sulfazamet,
Sulfinalol Hydrochloride, sulfinosine, Sulfinpyrazone,
Sulfisoxazole, Sulfomethoxazole, Sulfomyxin, Sulfonterol
Hydrochloride, sulfoxamine, Sulinldac, Sulmarin, Sulnida-
zole, Suloctidil, Sulofenur, sulopenem, Suloxifen Oxalate,
Sulpiride, Sulprostone, sultamicillin, Sulthiame, sultopride,
sulukast, Sumarotene, sumatriptan, Sumatriptan succinate,
Suncillin Sodium, Suproclone, Suprofen, suradista, suramin,
Surfomer, Suricamide Maleate, Suritozole, Suronacrine
Maleate, Suxemerid Sulfate, swainsonine, symakalim,
Symclosene, Symetine Hydrochloride, Taciamine Hydro-
chloride, Tacrine Hydrochloride, Tacrolimus, Tadalafil,
Talampicillin Hydrochloride, Taleranol, Talisomycin, talli-
mustine, Talmetacin, Talniflumate, Talopram Hydrochlo-
ride, Talosalate, Tametraline Hydrochloride, Tamoxifen,
tamoxifen citrate, Tampramine Fumarate, Tamsulosin, Tam-
sulosin Hydrochloride, Tandamine Hydrochloride, tan-
dospirone, tapgen, taprostene, Tasosartan, tauromustine,
Taxane, Taxoid, Tazadolene Succinate, tazanolast, tazaro-
tene, Tazifylline Hydrochloride, Tazobactam, Tazofelone,
Tazolol Hydrochloride, Tebufelone, Tebuquine, Teclozan,
Tecogalan Sodium, Teecleukin, Teflurane, Tegafur, Tegas-
erod, Tegretol, Teicoplanin, telenzepine, tellurapyrylium,
telmesteine, telmisartan, Teloxantrone Hydrochloride,
Teludipine Hydrochloride, Temafloxacin Hydrochloride,
Tematropium Methyl sulfate, Temazepam, Temelastine,
temocapril, Temocillin, temoporfin, temozolomide, temsi-
rolimus, Tenidap, Teniposide, Tenofovir, tenosal, tenoxicam,
tepirindole, Tepoxalin, Teprotide, terazosin, Terazosin
Hydrochloride, Terbinafine, Terbutaline Sulfate, Tercon-
azole, terfenadine, terfiavoxate, terguride, Teriparatide, Teri-
paratide Acetate, terlakiren, terlipressin, terodiline, Terox-
alene Hydrochloride, Teroxirone, tertatolol, Tesicam,
Tesimide, Testolactone, Testosterone, Tetracaine, tetrachlo-
rodecaoxide, Tetracycline, Tetracycline hydrochloride, Tet-
rahydrozoline Hydrochloride, Tetramisole Hydrochloride,
Tetrazolast Meglumine, tetrazomine, Tetrofosmin, Tetroqui-
none, Tetroxoprim, Tetrydamine, thaliblastine, Thalidomide,
Theofibrate, Theophylline, Thiabendazole, Thiamiprine,
Thiamphenicol, Thiamylal, Thiazesim Hydrochloride, Thi-
azinamium Chloride, Thiethylperazine, Thiithixene, Thime-
rfonate Sodium, Thimerosal, thiocoraline, thiofedrine, Thio-
guanine, thiomarinol, Thiopental Sodium, thioperamide,
Thioridazine, Thiotepa, Thiphenamil Hydrochloride, Thip-
hencillin Potassium, Thiram, Thozalinone, Threoxine,
Thrombin, thrombopoietin, thymalfasin, thymopentin, thy-
motrinan, Thyromedan Hydrochloride, Thyroxine, Tiacri-
last, Tiacrilast Sodium, tiagabine, Tiamenidine, tianeptine,
tiapafant, Tiapamil Hydrochloride, Tiaramide Hydrochlo-
ride, Tiazofurin, Tibenelast Sodium, Tibolone, Tibric Acid,
Ticabesone Propionate, Ticarbodine, Ticarcillin Cresyl
Sodium, Ticlatone, ticlopidine, Ticrynafen, tienoxolol, Tifu-
rac Sodium, Tigemonam Dicholine, Tigestol, Tiletamine
Hydrochloride, Tilidine Hydrochloride, tilisolol, tilnoprofen
arbamel, Tilorone Hydrochloride, Tiludronate Disodium,
tiludronic acid, Timefurone, Timobesone Acetate, Timolol,
Timolol meleate, Tinabinol, Timidazole, Tinzaparin
Sodium, Tioconazole, Tiodazosin, Tiodonium Chloride, Tio-
peridone Hydrochloride, Tiopinac, Tiospirone Hydrochlo-
ride, Tiotidine, Tiotropium, tiotropium bromide, Tioxida-
zole, Tipentosin Hydrochloride, tipranavir, Tipredane,
Tiprenolol Hydrochloride, Tiprinast Meglumine, Tipropidil
Hydrochloride, Tiqueside, Tiquinamide Hydrochloride,
tirandalydigin, Tirapazamine, tirilazad, tirofiban, tiropr-
amide, titanocene dichloride, Tixanox, Tixocortol Pivalate,
Tizanidine Hydrochloride, Tnmethobenzamide Hydrochlo-
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ride, Tobramycin, Tocamide, Tocamphyl, Tofenacin Hydro-
chloride, Tolamolol, Tolazamide, Tolazoline Hydrochloride,
Tolbutamide, Tolcapone, Tolciclate, Tolfamide, Tolgabide,
Tolimidone, Tolindate, Tolmetin, Tolnaftate, Tolpovidone,
5 Tolpyrramide, Tolrestat, Tolterodine, tolterodine tartrate,
Tomelukast, Tomoxetine Hydrochloride, Tonazocine Mesy-
late, Topiramate, topotecan, Topotecan Hydrochloride,
topsentin, Topterone, Toquizine, torasemide, toremifene,
Torsemide, Tosifen, Tosufloxacin, totipotent stem cell factor
io (TSCF), Tracazolate, trafermin, Tralonide, Tramadol, Tra-
madol Hydrochloride, Tramazoline Hydrochloride, tran-
dolapril, Tranexamic Acid, Tranilast, Transcamide, trastu-
zumab, traxanox, Trazodone Hydrochloride, Trebenzomine
Hydrochloride, Trefentanil Hydrochloride, Treloxinate,
15 Trepipam Maleate, Trestolone Acetate, tretinoin, Triacetin,
triacetyluridine, Triafungin, Triamcinolone, Triampyzine
Sulfate, Triamterene, Triazolam, Tribenoside, tricaprilin,
Tricetamide, Trichlonnethiazide, trichohyalin, triciribine,
Tricitrates, Triclofenol piperazine, Triclofos Sodium, trien-
20 tine, Trifenagrel, triflavin, Triflocin, Triflubazam, Triflumi-
date, Trifluoperazine Hydrochloride, Trifluperidol, Triflu-
promazine, Triflupromazine Hydrochloride, Trifluridine,
Trihexyphenidyl Hydrochloride, Trilostane, Trimazosin
Hydrochloride, trimegestone, Trimeprazine Tartrate,
25 Trimethadione, Trimethaphan Camsylate, Trimethoprim,
Trimetozine, Trimetrexate, Trimipramine, Trimoprostil, Tri-
moxamine Hydrochloride, Triolein, Trioxifene Mesylate,
Tripamide, Tripelennamine Hydrochloride, Triprolidine
Hydrochloride, Triptorelin, Trisulfapyrimidines, Troclosene
so Potassium, troglitazone, Trolamine, Troleandomycin, trom-
bodipine, trometamol, Tropanserin Hydrochloride, Tropic-
amide, tropine, tropisetron, trospectomycin, trovafloxacin,
trovirdine, Tryptophan, Tuberculin, Tubocurarine Chloride,
Tubulozole Hydrochloride, tucaresol, tulobuterol, turos-
35 teride, Tybamate, tylogenin, Tyropanoate Sodium, Tyrosine,
Tyrothricin, tyrphostins, ubenimex, Uldazepam, Unde-
cylenic Acid, Uracil Mustard, urapidil, Urea, Uredepa, uri-
dine triphosphate, Urofollitropin, Urokinase, Ursodiol,
valaciclovir, Valacyclovir hydrochloride, Valine, Valnoct-
4o amide, Valproate semisodium, Valproic Acid, valsartan,
vamicamide, vanadeine, Vancomycin, vaminolol, Vapiprost
Hydrochloride, Vapreotide, Vardenafil, Varenicline, variolin
B, Vasopressin, Vecuronium Bromide, velaresol, Velnacrine
Maleate, venlafaxine, Venlafaxine hydrochloride, Verado-
45 line Hydrochloride, veramine, Verapamil Hydrochloride,
verdins, Verilop am Hydrochloride, Verlukast, Verofylline,
veroxan, verteporfin, Vesnarinone, vexibinol, Vidarabine,
vigabatrin, vildagliptin, Viloxazine Hydrochloride, Vinblas-
tine Sulfate, vinburnine citrate, Vincofos, vinconate, Vin-
50 cristine Sulfate, Vindesine, Vindesine Sulfate, Vinepidine
Sulfate, Vinglycinate Sulfate, Vinleurosine Sulfate, vinore-
lbine, vinpocetine, vintoperol, vinxaltine, Vinzolidine Sul-
fate, Viprostol, Virginiamycin, Viridofulvin, Viroxime,
vitaxin, Voglibose, Volazocine, voriconazole, vorozole, vox-
55 ergolide, Wafarin, Xamoterol, Xanomeline, Xanoxate
Sodium, Xanthinol Niacinate, xemilofiban, Xenalipin, Xen-
bucin, Xilobam, ximoprofen, Xipamide, Xorphanol Mesy-
late, Xylamidine Tosylate, Xylazine Hydrochloride, Xylo-
metazoline Hydrochloride, xylose, yangambin, zabicipril,
60 zacopride, zafirlukast, Zalcitabine, Zaleplon, zalospirone,
Zaltidine Hydrochloride, zaltoprofen, zanamivir, zankiren,
zanoterone, Zantac, Zarirlukast, zatebradine, zatosetron,
Zatosetron Maleate, zenarestat, Zenazocine Mesylate, Zeni-
platin, Zeranol, Zidometacin, Zidovudine, zifrosilone, Zil-
65 antel, zilascorb, zileuton, Zimeldine Hydrochloride, Zinc
Undecylenate, Zindotrine, Zinoconazole Hydrochloride,
Zinostatin, Zinterol Hydrochloride, Zinviroxime, ziprasi-
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done, Zobolt, Zofenopril Calcium, Zofenoprilat, Zolamine
Hydrochloride, Zolazepam Hydrochloride, Zoledronate,
Zolertine Hydrochloride, zolmitriptan, zolpidem, Zomepirac
Sodium, Zometapine, Zoniclezole Hydrochloride, Zonis-
amide, zopiclone, Zopolrestat, Zorbamyciin, Zorubicin
Hydrochloride, zotepine, Zucapsaicin, and pharmaceutically
acceptable salts thereof.
EXAMPLE 1
The capsule as described herein is used to administer
leuprolide acetate for the treatment of prostate cancer. Leu-
prolide acetate (USP 31) is a synthetic nonapeptide agonist
analog of luteinizing hormone-releasing factor (LNHR). The
leuprolide acetate molecule is approximately 1209 Daltons
in weight and two to three nanometers in size. It is soluble
in aqueous media at a level of approximately 10 mg/mL. An
existing method of administering leuprolide via extended
release is disclosed in U.S. Pat. No. 5,728,396 filed Jan. 30,
1997 and incorporated herein by reference.
The nanochannel delivery device chip is installed in a
capsule as described herein and filled with a 5 mg/mL
leuprolide acetate solution (NDC number 0703-4014-18) for
use in the treatment of prostate cancer. The capsule is sized
to approximately 2.8 mL, so that the filled capsule contains
approximately 14 mg of leuprolide acetate. If stronger
concentrations of leuprolide acetate solution are used, the
capsule volume may be correspondingly reduced. The cap-
sule is implanted subcutaneously in the inner portion of the
upper arm or upper leg or in the abdomen. The capsule is
implanted, with optional use of a tissue separator, through a
small incision in a clinical outpatient procedure and
removed two to three months later through a small incision.
For implant and explant, a small amount of anesthetic is
used, for example, a 1% lidocaine injection at the site.
The micro- and nano-channel sizes of the nanochannel
delivery device are chosen (for example, according to the
model described in [Grattoni, A. Ferrari, M., Liu, X. Quality
control method for micro-nano-channels silicon devices.
U.S. Patent Application No. 61/049,287 (April 2008)]), to
provide a release rate of about 120 µg/day can be obtained
for about 90 days in certain embodiments.
In this example, the nanochannel delivery device configu-
ration with this behavior uses a 6x6 mm chip size, with 161
macrochannels with openings of 190x190 µm each, and
within each macrochannel approximately 23 rows of nano-
channel structures, consisting of 10 each of inlet and outlet
microchannels, connected through about 20 nanochannels
according to the description herein. The inlets and outlets are
approximately 5x5 µm in cross-section, with the inlets being
about 30 µm long and the outlets being about 1.6 µm long,
and the nanochannels are about 5µm long and 5µm wide
and 13 nm high. Other configurations with different dimen-
sions may be derived from the mathematical model that
yield approximately the same release rate and duration in
other examples.
EXAMPLE 2
The capsule and nanochannel delivery device are config-
ured and implanted as described in Example 1. However,
instead of administering leuprolide acetate, the capsule and
nanochannel delivery device administer letrozole for the
treatment of breast cancer. The limited success of chemo-
therapy for the treatment of breast cancer emphasizes the
need of novel preventive strategies to minimize the cancer
occurrence. Recent studies have highlighted that aromatase
46
inhibitors are promising chemopreventive agents for breast
cancer through inhibition of estrogen biosynthesis. In par-
ticular, research has suggested that letrozole is an ideal
candidate for chemoprevention for women in high risk
5 group such as BRCAI positive. However, the low efficacy
and the side effects associated with the conventional sys-
temic administration of letrozole are limiting factors for its
long term usage.
Breast cancer growth is highly dependent on estrogen,
to 
and thus inhibition of estrogen is highly effective for the
prevention of breast tumor development. Recent studies
have highlighted aromatase inhibitors such as anastrozole,
letrozole, and exemestane, as promising molecules that can
15 be used for chemoprevention of breast cancer. Aromatase
mediates biosynthesis of estradiol, the most potent form of
estrogen, from androgens by the cytochrome P450 enzyme
complex (Aromatase). Aromatase is present in breast tissue
and the nonsteroidal and steroidal aromatase inhibitors
20 reduce circulating estrogen level to 1% to 10% of pretreat-
ment levels, respectively. Therefore, inhibition of aromatase
is an important approach for reducing growth-stimulatory
effects of estrogens in estrogen-dependent breast cancer,
which constitutes approximately 60-70% of breast cancer.
25 Among the aromatase inhibitors, letrozole is a highly potent
non-steroid inhibitor which inhibits approximately 99% of
estrogen biosynthesis. Additionally, several studies and
clinical trials on chemotherapy of metastatic breast cancer
indicated higher efficacy with fewer side effects of letrozole
30 when compared to Tamoxifen. Hence, research suggests
letrozole as a candidate for the development of chemopre-
ventive therapy for women at increased risk of breast cancer.
However, the conventional oral administration of letrozole
showed increased risk of heart problems and osteoporosis.
35 The key for the success of chemoprevention for breast
cancer relies on long term delivery of specific drugs while
circumventing side effects. As opposed to the inefficient oral
administration, a constant local release of chemopreventive
agent (i.e. letrozole) in breast tissue could significantly
4o reduce occurrence of breast tumor as well as systemic side
effects. This shows promise for improvement in patient
quality of life.
It is believed that the implantable nanochanneled devices
according to the present disclosure will allow the constant
45 and sustained local release of letrozole in breast tissues and
significant reduction of estrogen dependent epithelial cell
proliferation with minimum toxicities.
Prior clinical trials employed letrozole daily doses of 2.5
mg. It is believed that the constant local release of letrozole
50 in breast tissues (utilizing nanochanneled devices according
to the present disclosure) would require lower dosage if
compared to oral delivery. In first analysis it is believed that
a local daily release in the range 25 to 50 ug could be
effective.
55 The achievement of an efficient chemopreventive therapy
by the use of long-term, constant release implants for local
administration of chemopreventive agents will have signifi-
cant impact on the quality of life of women in the high risk
group. It is believed that use of nanochannel delivery
6o devices according to the present disclosure will lead to
improved efficacy of therapy, as well as potential reduction
of drug doses and reduction of side effects through true
constant release. A reduction in the number of breast cancer
occurrences due to effective preventive therapy would also
65 have a positive economic impact on patients, their employ-
ers and insurers through lowered cost of treatment, fewer
medical visits, and less work time lost.
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The development of a reliable extended release implant-
able technology adds a new dimension to drug delivery for
breast cancer. Tumor treatment and the suppression of
metastasis and/or tumor recurrence are natural follow-on
developments. Technology enhancements to the initial plat-
form could support variable and programmed release,
including remote, interactive control of the implanted
device, further enabling capabilities to deploy multiple
drugs simultaneously. In vivo refilling could also extend the
functionality of the nanochannel device and also decrease
adverse events associated with explanation. As a general
drug delivery method, other indications may be identified,
broadening the applicability of the innovation.
EXAMPLE 3
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example 1.
However, instead of administering leuprolide acetate, the
capsule and nanochannel delivery device administer lapa-
tinib for the treatment of breast cancer.
EXAMPLE 4
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example I.
However, instead of administering leuprolide acetate, the
capsule and nanochannel delivery device administer bupe-
norphine for the treatment of opiate dependency.
EXAMPLE 5
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example 1.
However, instead of administering leuprolide acetate, the
capsule and nanochannel delivery device administer inter-
feron alpha implant for giant cell angioblastoma.
EXAMPLE 6
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example 1.
However, instead of administering leuprolide acetate, the
capsule and nanochannel delivery device administer zido-
vudine in an intravaginal treatment for preventing HIV
being transmitted from a pregnant mother to a child.
As used herein, the term "direct fluid communication" is
interpreted as fluid communication between two bodies that
are directly connected, e.g. such that fluid may exit one body
and immediately enter the second body without flowing
through an intermediate body. For example, in the embodi-
ment shown in FIGS. 3A-3G, outlet 70 is in direct fluid
communication with nanochannel 25. However, outlet 70 is
not in direct fluid communication with inlet 30, because fluid
must flow through an intermediate body (nanochannel 25)
after exiting inlet 30 and before entering outlet 70.
Furthermore, as used herein, the term "inlet" is interpreted
as a chamber or reservoir within a nanochannel delivery
device that initially retains a substance being delivered via
the nanochannel delivery device. Similarly, an "outlet" is
interpreted as a chamber or reservoir within a nanochannel
delivery device that retains a substance immediately prior to
the substance exiting the nanochannel delivery device.
All of the devices, systems and/or methods disclosed and
claimed herein can be made and executed without undue
experimentation in light of the present disclosure. While the
devices, systems and methods of this invention have been
48
described in terms of particular embodiments, it will be
apparent to those of skill in the art that variations may be
applied to the devices, systems and/or methods in the steps
or in the sequence of steps of the method described herein
5 without departing from the concept, spirit and scope of the
invention. All such similar substitutes and modifications
apparent to those skilled in the art are deemed to be within
the spirit, scope and concept of the invention as defined by
the appended claims.
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55 The invention claimed is:
1. A method of fabricating a nanochannel delivery device,
the method comprising:
providing first substrate;
forming a plurality of nanochannels on the first substrate;
60 filling in the plurality of nanochannels with a first sacri-
ficial material;
forming a plurality of inlet microchannels in the first
substrate;
filling in the plurality of inlet microchannels with a
65 second sacrificial material;
forming a capping layer that covers the plurality of
nanochannels;
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forming a plurality of outlet microchannels in the capping
layer;
removing the first sacrificial material from the plurality of
nanochannels; and
removing the second sacrificial material from the plurality
of inlet microchannels.
2. The method of claim 1, wherein an inlet microchannel
of the plurality of inlet microchannels is arranged perpen-
dicular to a primary plane of the first substrate.
3. The method of claim 1, wherein an outlet microchannel
of the plurality of outlet microchannels is arranged perpen-
dicular to a primary plane of the first substrate.
4. The method of claim 1, wherein an inlet microchannel
of the plurality of inlet microchannels is in direct fluid
communication with a nanochannel.
5. The method of claim 1, wherein an outlet microchannel
of the plurality of outlet microchannels is in direct fluid
communication with a nanochannel.
6. The method of claim 1, wherein the inlet and outlet
microchannels are patterned using a photolithography pro-
cess.
7. The method of claim 1, wherein each nanochannel is
between approximately one and ten nanometers deep.
8. The method of claim 1, wherein each nanochannel is
between approximately ten and twenty nanometers deep.
9. The method of claim 1, wherein the first sacrificial
material is subsequently removed by selective etching.
10. The method of claim 1, wherein the first sacrificial
material is tungsten.
11. The method of claim 1, wherein the second sacrificial
material is filled into the plurality of inlet microchannels so
that the second sacrificial material extends above the top of
the plurality of inlet microchannels and is planarized by
chemical-mechanical planarization (CMP).
50
12. The method of claim 1 wherein the capping layer is
selected from silicon nitride, silicon oxide, silicon carboni-
tride, silicon carbide, and silicon.
13. The method of claim 1, wherein the capping layer
5 comprises multiple depositions of materials comprising ten-
sile and compressive stresses such that the net capping layer
stress is tensile.
14. The method of claim 1, wherein the capping layer is
between approximately 0.5 and 1.0 microns thick.
15. The method of claim 1, wherein the capping layer is
l0 between approximately 1.0 and 2.0 microns thick.
16. The method of claim 1, wherein the capping layer is
between approximately 2.0 and 4.0 microns thick.
17. The method of claim 1, wherein the second sacrificial
material is subsequently removed by selective etching.
15 18. The method of claim 17, wherein the second sacrificial
material is selected from the group consisting of: tungsten,
copper, doped glass, and undoped glass.
19. The method of claim 1, wherein the first substrate
comprises a silicon-on-insulator wafer comprising an inter-
20 nal oxide layer.
20. The method of claim 19, wherein forming the plurality
of inlet microchannels comprises etching material from the
first substrate, and wherein the etching is terminated at the
internal oxide layer.
25 21. The method of claim 20, wherein forming a plurality
of inlet macrochannels comprises etching material from a
back side of the first substrate, and wherein the etching is
terminated at the internal oxide layer.
22. The method of claim 21, further comprising removing
30 of the internal oxide layer after etching material to form the
inlet microchannel and inlet macrochannels to open a path-
way between the inlet microchannels and inlet macrochan-
nels.
